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ABSTRACT	
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and the 
most current treatment for unresectable hepatocellular carcinoma is transarterial 
chemoembolization using drug-eluting beads (DEB-TACE). The concept of TACE 
might also technically be applicable to other types of hypervascular cancers such as 
renal cell carcinoma (RCC). The overall aims of this project were to improve the 
understanding of DEB-TACE as a treatment of unresectable HCC and to assess its 
feasibility in treating RCC.  
By using computerized tomography (CT) imaging before and early after DEB-TACE, 
in addition to the routine follow-up imaging, it was shown in study I that high arterial 
and low portal perfusion early after TACE indicated incomplete response with good 
diagnostic accuracy. Interestingly, it was also shown that portal perfusion of HCC was 
significantly higher in treated HCC compared to non-treated HCC (p = 0.01). 
In study II the drug delivery performance, safety, and the grade of necrosis after DEB-
TACE were compared to those of an alternative treatment, transarterial infusion (TAI) 
of doxorubicin-in-lipiodol emulsion. TAI is applied by injecting the emulsion in the 
vessel supplying a liver lobe without performing an embolization. Free doxorubicin 
and its metabolites were collected locally by placement of a pigtail catheter adjacent 
to the orifice of the liver veins and peripherally through standard venous blood 
samples and in urine samples. It was shown that the release of doxorubicin from the 
drug-eluting embolic agent was more controlled and prolonged. It was also shown 
that DEB-TACE caused milder adverse effects than TAI. The overall response 
(complete and partial response combined) for DEB-TACE was 91% compared to 67% 
for TAI, but this difference was not statistically significant. 
TAI of the doxorubicin-in-lipiodol emulsion followed by embolization of the HCCs’ 
feeding artery is known as conventional TACE (cTACE). In our center a switch from 
cTACE to DEB-TACE was made in 2009. A retrospective comparison between 
cTACE and DEB-TACE in this tertiary center (study III) showed no significant 
difference in overall survival between the two treatments. The adverse effects were 
significantly less common (p < 0.05) after DEB-TACE compared to after cTACE. 
In study IV, randomizing 12 patients with RCC eligible for surgery to either DEB-
TACE or transarterial embolization (TAE) using the same embolic agent as in DEB-
TACE, but unsaturated with doxorubicin, made it possible to evaluate the feasibility 
of these two techniques in treating RCC and to assess their effect using CT 
preoperatively and microscopy postoperatively. Both treatments were feasible. DEB-
DEB-TACE caused significantly more tumor necrosis (p < 0.018 on CT and p < 0.016 
on microscopy) than TAE. The results of the evaluation by CT correlated significantly 
with the results of the evaluation by the microscopy (p < 0.005), suggesting that CT 
can be used to evaluate the effect of embolization on RCC. The fact that viable cancer 
cells were seen on microscopy even when CT showed total necrosis of the treated 
RCC limits DEB-TACE to palliation.  
In conclusion, DEB-TACE changes HCC perfusion, causes fewer adverse effects 
compared to TAI and cTACE, and can be used to treat RCC. 
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1 INTRODUCTION	
1.1 INCIDENCE	OF	HEPATOCELLULAR	CARCINOMA	(HCC)	
Liver cancer is a common malignancy (figure 1). HCC represents up to 85% of all 
primary liver cancers 1. The incidence of HCC is increasing in Europe and globally 2. In 
most cases, HCC occurs in the presence of cirrhosis 2. Viral hepatitis (B or C), 
alcoholism, and non-alcoholic steatohepatitis are the most common underlying 
etiologies for cirrhosis2, 3. Vaccination against hepatitis B is recommended to all 
newborns, and antiviral therapies are recommended in patients with chronic hepatitis 
before cirrhosis can be established2.  
 
Diagnosis of HCC can usually be made non-invasively based on history, physical 
examination, blood tests, and radiology. There is a high diagnostic accuracy in patients 
with α-fetoprotein >500 ng/dl having a liver mass with a contrast enhancement pattern 
that suggests HCC as seen on computed tomography (CT) or magnetic resonance 
imaging (MRI) 3. 
 
 
 
Figure 1. The age-standardized incidence rate (ASR) of liver cancer 2018 (source: GLOBOCAN 2018, 
Graph production: IARC, http://gco.iarc.fr/today, world Health Organization). 
 
 
2 
1.2 PROGNOSIS	OF	HCC	
The majority of patients suffering from HCC have an underlying liver disease that can 
impair liver function, cause symptoms, and affects patient´s survival rate. That is why 
the prognostic evaluation of HCC must take into consideration the degree of liver 
function impairment and the cancer-related symptoms in addition to the basic tumor 
stage. Patient survival is related to the HCC stage, which is also important when 
choosing the treatment (figure 2). This can explain why survival ranges from 3 months 
in patients with late-stage HCC to more than 60 months in patients with very early stage 
HCC. 
 
 
Figure 2. The European Association for the Study of the Liver (EASL) Clinical Practice Guidelines2: 
Management of hepatocellular carcinoma (Hepatology, 2018). PS = Performance status. BSC = Best 
supportive care. 
1.3 STAGING	OF	HCC	
The Tumor, Node, Metastases (TNM) staging system does not provide information 
about liver function or the symptoms the patient is suffering from. These are two crucial 
factors when determining which treatment is suitable for a certain patient with HCC. 
The Child–Pugh system is widely used to grade the impairment of liver function. It 
divides patients into three groups, A, B and C (Table 1). This system scores blood 
bilirubin, blood albumin, prothrombin time or international normalized ratio (INR), 
ascites, and encephalopathy as demonstrated in Table 2.  
Table 1. The three classes of Child–Pugh scores according to the Barcelona Clinic Liver Cancer staging 
system. 
Class A Normal liver function (scoring 5–6 points) 
Class B Mild to moderate deterioration of liver function (scoring 7–9 points) 
Class C Severe deterioration of liver function (scoring 10–15 points) 
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Table 2. The Child–Pugh scores for five clinical measurements according to the Barcelona Clinic Liver 
Cancer staging system. Each is scored 1–3. 
 1 point 2 points 3 points 
Blood bilirubin  
mmol/L (mg/dL) 
<34 (<2) 34-50 (2-3) 
 
>50 (>3)  
 
Blood albumin g/dL >3.5 2.8–3.5 <2.8 
Prothrombin time or 
INR <4.0 
<1.7 
4.0-6.0 
1.7-2.3 
>6.0 
>2.3 
Ascites 
None Mild Moderate to severe 
Encephalopathy None 
Grade I-II Grade III-IV 
 
 
1.4 PERFORMANCE	STATUS		
The patient’s performance status (PS) is used to grade the symptoms the patient is 
suffering from. PS is graded from 0 to 5 according to the Eastern Cooperative Oncology 
Group (ECOG) where grade 0 represents the status of a fully active individual and 
grade 5 represents the status of a dead individual (Table 3).  
 
Table 3. Performance status system developed by the Eastern Cooperative Oncology Group (ECOG) 
published in 1982. 
GRADE ECOG PERFORMANCE STATUS 
0 Fully active. 
1 Restricted in activity but ambulatory and able to carry out work of a light or sedentary 
nature. 
2 Ambulatory and capable of self-care but unable to do any work. Ambulatory more than 
50% of waking hours. 
3 Capable of only limited self-care. Confined to bed or chair for more than 50% of waking 
hours. 
4 Completely disabled. 
5 Dead. 
4 
1.5 BARCELONA	CLINIC	LIVER	CANCER	(BCLC)	STAGING	SYSTEM	The	BCLC	is	a	staging	system	consisting	of	five	stages	that	are	determined	depending	on	the	size	of	the	HCC,	number	of	lesions,	PS,	and	liver	function	4.			
• Stage 0. Tumor size is less than 2 cm, the individual feels well (PS 0), and the 
liver function is normal (Child–Pugh A)  
• Stage A. A single tumor less than 5 cm, or up to three tumors all less than 3 cm. 
The person feels well and is active (PS 0), and the liver is working well (Child–
Pugh A or B)  
• Stage B. Multiple tumors in the liver, but the person feels well (PS 0) and the 
liver is working well (Child–Pugh A or B) 
• Stage C. The cancer has spread into the blood vessels, lymph nodes, or other 
body organs. Or the individual does not feel well (PS 1 or 2). The liver is still 
functioning (Child–Pugh A or B)  
• Stage D. Severe liver damage (Child–Pugh C) or the person is not well and 
needs help in being looked after (PS 3 or 4). 
1.6 DIAGNOSIS	OF	HCC	
The classical presentation of a patient with HCC is upper abdominal pain, weight loss, 
and blood tests suggesting impaired liver function. Some patients present with acute 
abdominal catastrophe due to HCC rupture with bleeding. Nowadays many HCCs are 
detected on ultrasound screening of patients with liver cirrhosis 5, i.e. patients at risk.  
1.7 IMAGING	OF	HCC	
Imaging such as CT or MRI is required in order to diagnose HCC, to evaluate the effect 
of the given line of therapy, and for the follow-up 6. The CT examination should 
include a non-contrast phase, a late arterial phase, a venous (parenchymal) phase, and a 
late venous phase (excretory). As for MRI, a dynamic contrast-enhanced MRI is needed 
6. In the setting of liver cirrhosis, international guidelines have set contrast enhancement 
in the arterial phase (wash in) and hypoattenuation (CT) or hypointense signal (MRI) in 
the portal or delayed phase (wash out) as the criteria for HCC diagnosis 5. Both for CT 
and MRI the hyper- and hypo- appearances are determined in relation to adjacent 
parenchyma. In HCC with atypical contrast enhancement (about 30% of all HCCs), 
biopsy can settle the diagnosis 2,7 .  
1.7.1 Contrast	enhanced	ultrasound	(CEUS)		
CEUS is not recommended as a first-line modality to diagnose HCC because it is 
difficult to scan the whole liver during the short arterial phase2. Some studies 2,7,8 
showed that cholangiocarcinoma sometimes has a similar enhancement pattern (wash in 
and wash out) and might simulate HCC when using CEUS. Ultrasound is commonly 
used for surveillance for at-risk patients every 6 months2, 7, and CEUS can be useful 
when CT and MRI are contraindicated or inconclusive2. 
1.8 LIVER	PERFUSION	CT		
In 2001, Cuenod et al. published their article “Early changes in liver perfusion caused 
by occult metastases in rats: detection with quantitative CT” 9. Since then, liver 
perfusion CT has been a subject of several studies, some of which were conducted at 
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Karolinska Institutet. This new technique is basically a repetitive imaging (e.g. 28 scans 
over 50 s) of the liver to obtain CT images during the contrast enhancement of this 
organ (and eventual tumors in it) 10-12, 14. This technique can be used to quantify tumor 
vascularization (i.e., to measure the enhancement and obtain curves) (figure 3). Placing 
the marker on the region of interest on the CT image is done manually. The computer 
will then place the marker on the same region in all other maps (figure 4). The 
computer calculates arterial liver perfusion (ALP), portal liver perfusion (PLP), and the 
hepatic perfusion index (HPI), which is equal to ALP / (ALP + PLP) (figure 5). 
The evolution toward HCC is characterized by arterialization of the blood supply and 
sinusoidal capillarization 13. Quantitative assessment of HCC using liver perfusion CT 
was shown to have the potential to reduce false-positive findings, thus improving 
the specificity of HCC diagnosis14. 
 
 
Figure 3. A liver perfusion CT image (left) and the graph (right) obtained. The red line represents arterial 
enhancement (obtained from placing the marker of the region of interest on the aorta, as shown on the CT 
image on the left), while yellow line represents the portal enhancement obtained from placing the marker 
on the portal vein (not shown on this CT image). 
 
The fact that increased attenuation is related to the amount of the contrast uptake by the 
tissue makes it possible to use conventional contrast-enhanced CT to detect metastasis 
and HCC in the liver (and other tumors in other organs) where the enhancement at a 
certain time is captured on an image, e.g. at the arterial phase. Dynamic acquisition of 
the liver (as in perfusion CT) before, during, and after intravenous contrast 
administration allows for the recording of changes in attenuation during the contrast 
perfusion across the capillary basement membrane from the intravascular to the 
extracellular space. Changes in attenuation when the contrast is in the intravascular 
space reflect the blood flow, while the attenuation in the same tissue when the contrast 
is in the extracellular space reflects the blood volume15. The liver has a dual blood 
supply (arterial and from the portal vein). Placing the marker of the region of interest 
(the software calculates the values within this marker) on an artery (e.g. the aorta) 
would produce a graphic function showing the changes in attenuation. The same applies 
to the portal vein (figure 3). Maximum splenic or renal contrast enhancement is used to 
mark the end of the arterial perfusion and the start of the portal perfusion when 
calculating ALP and PLP12. 
6 
 
 
 
 
Figure 4. Axial CT images from liver perfusion CT (a). The region of interest (HCC treated by DEB-
TACE) is marked by a circle on the PLP map (b). The software marks the same region on the ALP (c) and 
the HPI (d) color maps. 
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Figure 5. From left to right; upper row: maximal intensity projection (MIP) image, Blood flow color map, 
Blood volume color map; middle row: ALP color map, PLP color map, HPI color map; lower row: 
parameters table, values, graph. 
 
When performing liver perfusion CT to diagnose a liver tumor (primary or metastatic) 
and/or to assess the effect of the given treatment, the contrast concentration should not 
be less than 300 mg/ml, and the optimal contrast dose is 40–60 ml with an injection rate 
of 4 ml/second15. 
1.8.1 MRI	
MRI has gained increasing importance in HCC diagnostics and for assessing the effect 
of a given therapy. HCC is known to have a slightly higher signal than adjacent liver 
tissue on non-enhanced T2-weighted images and to have a hyperintense signal during 
the arterial phase due to HCC’s known hypervascularity 2. Although the sensitivity and 
specificity of MRI are similar to or slightly higher than CT, MRI’s sensitivity is lowest 
when the tumor is less than 2 cm in size 3,6. 
Diffusion weighted imaging is an MRI sequence that can assess the random motion of 
water molecules in a tissue. Tumors tend to have high signal intensity on such imaging 
due to restriction of the motion of water molecules 7.  
 
8 
1.9 TREATMENT	OF	HCC	(IN	LINE	WITH	EASL	RECOMMENDATIONS)	
Up to 27% of patients with HCC are considered operable. The rest might be candidates 
for thermal ablation, trans-arterial chemoembolization (TACE), radio embolization, 
percutaneous ethanol injection, or systemic sorafenib treatment. Of these therapies, 
TACE is the most commonly used therapy to treat HCC 2, and TACE is recommended 
for patients with HCC at BCLC stage B (figure 2).  
1.9.1 Surgery	and	transplantation	for	HCC	
Surgical resection is the treatment of choice in patients without liver cirrhosis, without 
extrahepatic spread, and who present with a solitary HCC. This includes patients with 
Child–Pugh class A 16. Liver transplantation is reserved for patients who do not 
consume alcohol or other addictive substances and in whom the HCC meets the Milan 
criterion (single HCC with a size of 5 cm or less or 2–3 HCCs each with a size of 3 cm 
or less). Liver transplantation might be the optimal treatment for patients with Child–
Pugh class C because it provides the patient with a non-cirrhotic liver17. Surgery and 
transplantation result in a 5-year survival rate of 60–80% 18,19.  
1.9.2 Ablation	of	HCC	
In patients unfit for surgery, ablation is the first line of treatment 2. There are different 
techniques of local ablative therapies that are used today, including radiofrequency, 
microwaves, percutaneous ethanol injection, cryoablation, and interstitial laser 
coagulation irreversible electroporation. The choice of therapy has been the subject of 
much research 20, 21. Of these ablative therapies, radiofrequency ablation is the most-
assessed alternative 2. Surgery and ablation in conjunction are chosen to treat 30–40% 
of patients with HCC 2. 
1.9.3 TACE	
TACE is a novel minimally invasive palliative treatment of unresectable HCC. TACE is 
also used to reduce the HCC burden enabling the patient to wait for liver 
transplantation22-24. TACE has been used to treat colorectal liver metastasis, uveal 
malignant melanoma liver metastasis, and neuroendocrine liver metastasis6-8. By 
inducing ischemia in combination with having a high intratumoral concentration of a 
cytotoxic agent, total or partial tumor necrosis can be obtained. This high concentration 
of the cytotoxic agent cannot be reached by administrating the agent intravenously 
without severe side effects25. 
The endovascular procedure is carried out under fluoroscopy guidance by an 
interventional radiologist. A sheath (usually 5 Charrière in caliber) is inserted in the 
common femoral artery to gain vascular access. Through this sheath, a guiding catheter 
is passed on a guiding wire and placed with its tip preferably in the common hepatic 
artery. A micro catheter is then placed through the guiding catheter on a micro guiding 
wire with its tip in the tumor-feeding vessel(s) (figure 6). 
TACE is performed by injecting lipiodol (a poppy seed oil) mixed with a cytotoxic 
agent, followed by injection of an embolic agent made of an absorbable gelatin sponge 
(Gelita-spon®, Gelita Medical GmbH, Eberbach, Germany). This procedure is 
currently named conventional TACE (cTACE) 26. Drug-eluting beads are an embolic 
agent consisting of micro particles made of polyvinyl alcohol saturated with a cytotoxic 
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agent. When the drug-eluting beads are injected via the micro catheter, the procedure is 
called drug-eluting beads TACE (DEB-TACE) 25. Both procedures are carried out until 
total stasis in the feeding artery is reached. The micro catheter can be re-placed in 
another tumor-feeding artery in order to inject the same mixture/suspension into another 
vessel supplying another portion of the same HCC or supplying a different HCC.  
Micro spheres made of polyvinyl alcohol cross-linked with acrylic polymer can be 
saturated with doxorubicin. When these micro spheres are injected into the arterial 
mesh supplying the HCC, they cause ischemia (due to embolization) and a 
simultaneous intratumoral release of doxorubicin.  
The embolic agent (particles) is available in different sizes, including 75–150, 100–300 
and 300–500 µm. Recently several manufacturers have even produced 40 µm particles. 
The particles (2 ml) are saturated with 75 mg doxorubicin at the pharmacy and 
delivered to the intervention suite in a 5 ml syringe containing 2 ml particles and 3 ml 
supernatant. The suspension is mixed with contrast agent before it is injected via the 
micro catheter. This makes the suspension detectable by fluoroscopy and makes the 
injection more controllable because it is not desired to inject the suspension vigorously 
and force it to reflux and fill arteries supplying non-tumorous tissue.  
Lipiodol is a mixture of di-iodinated long-chain ethyl esterases of fatty acids 27-28. The 
fact that lipiodol contains 480 mg iodine/ml makes lipiodol detectable by fluoroscopy. 
Lipiodol generates a transient embolization of the sinusoidal vessels in animal studies 
29,30, and lipiodol has been reported to accumulate in HCCs for up to several months28.  
The capability of lipiodol as a liquid substance to penetrate deeply into the sinusoidal 
vessels and perhaps also to portal vessels as suggested in animal studies30- 32 led to the 
assumption of its superiority to DEB-TACE, where the particles, saturated with the 
cytotoxic agent, remain in the arterioles. An earlier comparison of doxorubicin 
pharmacokinetics released from drug-eluting beads with that released from 
doxorubicin-in-lipiodol emulsion (in transarterial infusion (TAI)) in healthy pigs 
indicated that the release of doxorubicin when applying TAI is faster and more 
extensive in vivo than the doxorubicin release from the beads, resulting in higher 
systemic plasma exposure 32, 33. 
The evaluation of the results of the endovascular treatment (TACE/TAI) is carried out 
using CT or MRI. Because lipiodol delivered to the HCC is radio-opaque and might 
mask contrast enhancement on CT, MRI is considered to be a better choice to evaluate 
the effect after cTACE and TAI. Both CT (figure 7) and MRI are suitable to evaluate 
the effect after DEB-TACE because of the lack of radio-opaque mass in the treated 
tumor at the time of evaluation, which is preferably four weeks after the endovascular 
treatment.  
There are several systems to evaluate therapy response, including the World Health 
Organization (WHO) criteria, Response Evaluation Criteria in Solid Tumors (RECIST), 
modified RECIST (mRECIST), and the European Association for the Study of the 
Liver (EASL) criteria (Table 4).  
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Figure 6. Subtraction angiography images showing the contrast enhancement in three HCCs, the micro 
catheter (black arrow), and the guiding catheter (double black arrows). 
 
Figure 7. CT images before and after TACE (the same case as in figure 6). The HCCs are indicated by 
arrows. 
 
 
 
 
 
 
 
   11 
 
 
 
Table 4. WHO, RECIST, mRECIST, and EASL criteria  
Response WHO RECIST mRECIST EASL 
Complete  Disappearance of 
the lesions 
Disappearance of 
the lesions 
No contrast 
enhancement in 
the lesion on CT 
or MRI 
No contrast 
enhancement in 
the lesion on CT 
or MRI 
Partial  50% or more 
decrease in the 
sum of the cross-
products of the 
target lesion 
30% or more 
decrease in the 
sum of the 
diameters of the 
target lesion 
50% or more 
decrease in the 
sum of the 
diameters of the 
area showing 
contrast 
enhancement 
30% or more 
decrease in the 
sum of the 
diameters of the 
area showing 
contrast 
enhancement 
Stable disease Neither partial 
response nor 
progressive 
disease 
Neither partial 
response nor 
progressive 
disease 
Neither partial 
response nor 
progressive 
disease 
Neither partial 
response nor 
progressive 
disease 
Progressive 
disease 
25% or more 
increase in the 
cross-product of 
target lesions or 
the appearance of 
new lesions 
20% or more 
increase in the sum 
of the diameters 
25% or more 
increase in the 
sum of the 
diameters of the 
area showing 
contrast 
enhancement 
20% ore more 
increase in the 
sum of the 
diameters of the 
area showing 
contrast 
enhancement 
 
In our center, we shifted from cTACE to DEB-TACE in February–April 2009. The 
comparison between cTACE and DEB-TACE has been the subject of several studies 
regarding aspects such as overall survival, toxicity, and adverse effects. The results 
have differed from showing the superiority of DEB-TACE regarding survival and 
complications to showing no difference between the two regimes (Table 5A and 5B). 
None of these studies were conducted in Scandinavian patients.  
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Table 5A. Examples of studies regarding patient survival after cTACE vs. DEB-TACE 
Type of study Survival (cTACE vs. DEB-TACE) 
Prospective studies No significant difference in overall survival (Reyes et al. 2009, Lammer et al. 2010, 
Sacco et al. 2011, Van Malenstein et al. 2011, Golfieri et al. 2014). 
 
 
Retrospective studies 
Three studies showed significantly longer survival in patients treated with DEB-
TACE (Dhanasekaran et al. 2010, Wiggermann et al. 2011, Nicolini et al. 2013). 
One study showed significantly longer survival in the cTACE group (Scartozzi et 
al. 2010). 
Two studies showed no difference in survival between the two treatments (Megías 
Vericat et al. 2015, Kloeckner et al. 2015).   
 
 
Table 5B. Examples of studies regarding adverse events after cTACE vs. DEB-TACE 
Type of study Adverse events (cTACE vs. DEB-TACE) 
 
Prospective studies 
Three studies showed fewer adverse events with DEB-TACE (Van Malenstein et al. 
2011, Ferrer et al. 2011, Lammer et al. 2010). 
Three studies showed no difference in adverse events (Golfieri et al., 2014; Sacco et 
al. 2011; Wiggermann et al. 2011). 
 
Retrospective studies 
Four studies showed higher incidences of post-embolization syndrome in the cTACE 
group (Varela et al. 2007, Megías Vericat et al. 2015, Arabi et al. 2015, Liu et al., 
2015). 
 One study showed no difference in adverse events between cTACE and DEB-
TACE (Scartozzi et al. 2010). 
 
It is also imperative to mention that TACE generally lacks a standard protocol 34. 
Variables like patient selection, preparation of the emulsion, embolization endpoint, use 
of the supernatant in the syringe, and size of the embolic agent differ from one center to 
another. 
Doxorubicin is a multitarget, broad-spectrum cytotoxic drug that can be delivered intra-
arterially, either as a doxorubicin-in-lipiodol emulsion or by injecting polyvinyl alcohol 
particles saturated with doxorubicin. These particles act as a drug-eluting embolic 
agent. The polyvinyl alcohol particles incorporate chains of acylamido-2-
methylpropane sulfonate sodium salt 35, and the positively charged doxorubicin binds to 
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the negatively charged sulfonate groups in the particles. The saturation and the release 
of doxorubicin from this embolic agent (particles) are driven by ion-exchange and 
diffusion 36, 37, 38. 
Early pharmacokinetic studies showed slow release of doxorubicin from the particles 
with subsequent low systemic plasma exposure 36-38 causing milder doxorubicin-related 
side effects compared with doxorubicin-in-lipiodol emulsion.  
1.9.4 Systemic	therapy	for	HCC	
This course of action is considered when other treatments are not suitable, e.g. the 
presence of distant metastases or tumor thrombus. Sorafenib (which is an oral multi-
tyrosine kinase inhibitor) is still considered to be the first-line therapy that can increase 
the survival by 2.8 months in patients with advanced HCC. This was shown by a 
double-blinded, placebo-controlled phase III study 40. 
1.10 OTHER	TRANSARTERIAL	THERAPIES	FOR	HCC	
1.10.1 TAI	
TAI is also known as transarterial oily infusion and is distinguished from TACE in that 
no embolization is performed 41. This is a transcatheter treatment carried out by 
injecting an emulsion of doxorubicin-in-lipiodol either segmentally (in an artery 
supplying a liver segment) or lobar (in the right or left hepatic artery) without 
performing further embolization (apart from the transient embolization caused by the 
emulsion). This method of infusion makes it possible to treat several tumors in one liver 
lobe (or in a liver segment), but it also means placing the lipiodol with the cytotoxic 
agent in the entire right or left liver lobe and exposing a large portion of the cirrhotic 
liver to the cytotoxic agent. This might lead to further deterioration of liver function. 
1.10.2 Trans	arterial	embolization	(TAE)		
TAE using particles that are not saturated with cytotoxic drugs is also used to treat HCC 
and is referred to as bland embolization in the literature. In fact, the advantage of TACE 
over TAE has been controversial 42. Some studies have suggested that DEB-TACE and 
TAE have similar necrotic effects and some suggest that DEB-TACE contributes to 
longer time to disease progression 43. 
1.10.3 Radioembolization		
Transarterial radioembolization is performed by injecting a radioactive substance 
(Iodine-131-labelled lipiodol) 44 or by injecting microspheres containing Yttrium-90 45 
into the hepatic artery. The portion of the radioactive substance reaching the HCC emits 
low-penetration radiation causing tumor necrosis. This treatment is preceded by a 
prophylactic trans-catheter coiling of the extrahepatic branches and/or gastroduodenal 
artery if necessary. After coiling these arteries, 99Tc macroaggregated albumin is 
injected into the hepatic artery. The patient is then examined using single-photon 
emission CT imaging to calculate the dose around the HCC and the hepato-pulmonary 
shunt fraction. The result of these calculations might be the basis on which the 
treatment would be contraindicated (if dangerously high). One liver lobe is treated at a 
time. 
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Although radiation segmentectomy seems very promising, this technique has only very 
recently emerged and there are no randomized controlled trials testing embolization 
with particles containing Yttrium-90 46. 
1.11 RENAL	CELL	CARCINOMA	(RCC)	
Incidence 
The age-standardized incidence rate of kidney cancer globally is shown in figure 8. 
Approximately 90% of all kidney cancers are RCCs 47, and 20–30% of all patients are 
diagnosed with metastatic disease48. All solid renal masses are suspected to be RCC 
until proven otherwise. Researchers have established that the incidental detection of 
renal cell carcinoma is rising because of increased use of imaging procedures 49.  
 
Figure 8. The age-standardized incidence rate (ASR) of kidney cancer 2018 (source: GLOBOCAN 2018, 
Graph production: IARC, http://gco.iarc.fr/today, world Health Organization). 
 
1.12 DIAGNOSIS	OF	RCC	
The typical presenting symptoms of renal malignancy are flank pain, macro hematuria, 
and a palpable abdominal mass. These symptoms are correlated with poor prognosis 50. 
RCC does not have to be symptomatic in itself, and sometimes the reason the patient 
seeks care is symptoms related to metastases from RCC such as skeletal pain or 
respiratory tract symptoms 51. 
 
1.13 IMAGING	OF	RCC	
The modalities of ultrasound, CT, and MRI are used for the detection of renal masses. 
Contrast-enhanced ultrasound is the first choice in patients with impaired renal function 
   15 
 
or when iodinated contrast media or gadolinium are contraindicated. For detecting lung 
metastasis (and affected mediastinal lymph nodes), CT is the most commonly used 
modality 52. Diagnoses of small renal masses using both CT and MRI is based on the 
contrast enhancement pattern of the renal mass in order to differentiate these masses 
from non contrast-enhancing renal cysts. In our center we recommend a CT scan 
protocol that includes non-contrast phase, late arterial phase, parenchymal phase, and 
excretory phase imaging. Scan start for the phases with contrast media was determined 
using a bolus-tracking technique, but diagnosing angiomyolipoma with minimal fat 
component and oncocytoma is still a challenge for radiologists regardless of modality, 
i.e. CT or MRI 53,54. All three modalities mentioned above can nowadays be used when 
applying image-guided therapies.  
1.14 BIOPSY	OF	RCC	
Percutaneous needle biopsy is usually efficient to settle the diagnosis of renal masses 
and helps to avoid unnecessary surgery for benign renal masses. Biopsy helps us to 
make a treatment decision especially in cases where the patients are not fit for surgery. 
Core biopsies have high specificity (98–100%) and high sensitivity (86–100%) for the 
diagnosis of malignancy 54.   
1.15 PROGNOSIS	AND	STAGING	OF	RCC	
Unlike patients with localized RCC, the prognosis for patients with metastasized RCC 
is extremely poor 48. Due to the increasing use of radiological imaging, 15–48% of 
RCCs are nowadays detected incidentally in earlier stages 51. As mentioned earlier, all 
renal masses are suspected to be malignant, but cysts and lesions with cystic 
components are challenging for the evaluating radiologist. The Bosniak classification 
(table 6) of cystic renal masses is a widely used instrument that categorizes cystic renal 
masses into five groups based on CT findings. This classification is used to estimate the 
risk of malignancy and to indicate the management line 55.  
Table 6. The Bosniak classification of cystic renal masses 55. 
Bosniak class Risk for malignancy (%) 
1 0 
2 0 
2F 25 
3 54 
4 100 
F = follow-up. 
The TNM 2010 classification is still of very high value 56 as a possible tool to assist in 
choosing between nephrectomy and nephron-sparing surgery. The prognosis of RCC is 
affected by histological, clinical, and molecular factors 57, and researchers have 
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suggested that in addition to PS, paraneoplastic signs such as hypoalbuminemia, weight 
loss, and malaise are significant predictors of worse survival in patients with RCC 56. 
R.E.N.A.L score (Table 7) reflects the anatomical factors and their impact on post-
treatment complications. R.E.N.A.L scores of 4–6, 7–9, and 10–12 are referred to as 
low, medium, and high respectively. Higher R.E.N.A.L scores suggest more difficult 
and more complicated operations. This system can be helpful in choosing between 
nephrectomy, nephron-sparing surgery, and thermal ablation 57. 
 
Table 7. R.E.N.A.L scoring system 57 
  1 point 2 points 3 points 
R Maximum radius 
(cm) 
≤4 >4 but <7 ≥7 
E Exophytic ≥50% <50%  
N Nearness/Distance to 
collecting system 
(mm) 
≥7 >4 but <7 ≤4 
A Anterior (A) 
Posterior (P) 
Nether A nor P (X) 
A, P, or X instead 
of pints 
A, P, or X instead 
of points 
A, P, or X instead 
of points 
L Location in relation to 
polar lines 
Above upper or 
below lower polar 
line 
Lesion crosses 
polar line 
>50% of the mass 
crosses the axial 
renal midline or is 
lying between the 
polar lines 
 
 
1.16 TREATMENT	OF	RCC	
Localized RCCs are usually managed by nephron-sparing surgery or by radical 
nephrectomy 58-62. Active surveillance and thermal ablation have become the preferred 
choices of management for patients who are unfit for surgery and having small renal 
masses 63-65. The size of an RCC, its localization, and the distance between the RCC and 
other structures, such as the ureter, renal blood vessels, or intestine, are factors that can 
rule out ablation as a therapy choice 66-68.  
The efficacy of embolization to treat bleeding angiomyolipoma and RCC-related 
hematuria has been studied 69, but earlier studies were not randomized 24 and did not 
discuss the cytoreductive effect of embolization 70-72. 
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1.16.1 Systemic	and	adjuvant	therapy		
Significant uncertainties remain, although retrospective cohort studies suggest a 
potential benefit from combining systemic therapies in different orders 73. Despite the 
fact that RCC is known to be resistant to chemotherapy 74, the combination of systemic 
doxorubicin and gemcitabine in treating sarcomatoid RCC has been reported to result in 
a partial response albeit with a high toxicity profile 75. Thus, it seems reasonable to 
study whether doxorubicin delivered at high local concentrations to the tumor combined 
with embolization of the tumor-feeding vessel, i.e. using the DEB-TACE technique, can 
overcome the RCC’s resistance to chemotherapy 75. No evidence supporting the use of 
adjuvant therapy after surgery is available. Radiotherapy is limited to treating 
pulmonary and skeletal metastasis from RCC 53 mainly to decrease the pain these 
skeletal metastases cause or to decrease the risk of a pathological fracture.  
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2 AIMS	
2.1 GENERAL	AIMS	
The aims of this thesis were to increase the understanding of doxorubicin-eluting beads 
transarterial chemoembolization (DEB-TACE) as a treatment for intermediate stage 
hepatocellular carcinoma (HCC) and to investigate the possibility of its use in the 
treatment of renal cell carcinoma (RCC). 
2.2 SPECIFIC	AIMS		
Paper I 
To prospectively monitor changes in HCC perfusion early after DEB-TACE and to 
evaluate possible parameters that might predict the response to the teatment. 
Paper II 
To study the in vivo delivery of doxorubicin, short-term treatment safety and tumor 
response after transarterial infusion and DEB-TACE in HCC.  
Paper III 
To compare DEB-TACE with conventional transarterial embolization regarding overall 
survival and adverse events in HCC patients. 
Paper IV 
To assess the feasibility, safety, and cytoreductive effect after DEB-TACE and 
transarterial embolization to treat localized RCC.
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3 MATERIALS	AND	METHODS	
All studies were approved by the regional ethical review board and complied with the 
Declaration of Helsinki. Informed consent was obtained from all patients except for 
those included in paper IV (retrospective study) where data were retrieved from patient 
records. 
3.1 PAPER	I	
This was a prospective dual-center observational study conducted at Karolinska 
University Hospital, Stockholm, and University Medical Center Mannheim, Mannheim. 
During the period June 2013–February 2015, 24 patients (15 men and 9 women with a 
mean age of 69 years; range 54–79 years) eligible for DEB-TACE were recruited.  
3.1.1 Inclusion	criterion		
- Liver cirrhosis with unresectable or multi-nodular HCC eligible for DEB-TACE 
according to the BCLC criteria .   4
3.1.2 Exclusion	criteria		
- Atypical lesions, including hypovascular HCC  
- Previous radiofrequency ablation  
- Previous systemic treatment (e.g. anti-angiogenic therapy) 
- Known hypersensitivity to iodide contrast agent 
- Glomerular filtration rate below 45 mL/ min 
- Contraindications for CT such as pregnancy  
3.1.3 The	endovascular	procedure	
DEB-TACE was carried out, after sedation, via femoral access. The tip of a micro 
catheter was placed in the HCC’s feeding artery/arteries and drug-eluting beads with a 
size of 300 to 500 µm were injected. The treatment was ended when complete stasis of 
intratumoral arteries (as seen on subtraction angiography) was reached or when the 
maximum doxorubicin dose of 150 mg had been given. When the maximum dose was 
reached without complete stasis, particles not saturated with doxorubicin were injected 
until complete embolization. 
3.1.4 Perfusion	CT	examination	
CT examinations were performed before and after the DEB-TACE treatment. A 
second-generation 64-slice dual-source CT was used to examine all patients 
(SOMATOM Definition Flash, Siemens Healthcare, Forchheim, Germany). Perfusion 
CT protocols are detailed in Table 8. The markers of regions of interest were placed in 
the portal vein and kidney cortex manually 12 in order to be able to discriminate arterial 
from portal venous perfusion. Perfusion	CT examinations were performed before and 
shortly after the DEB-TACE treatment (mean interval of 12 ± 24.74 hours, range 1–48 
20 
hours). In case of repeated DEB-TACE treatments, only the first DEB-TACE was 
included in this study. To avoid eventual data clustering, only the largest HCC was 
included when a patient had multiple lesions. 
 
 
 
Table 8. CT liver perfusion protocols in study I. 
Parameter Protocol A (n = 10) Protocol B (n = 14) 
Scan width (cm) 14.8–18.2 26.5–34.3 
Scan delay (s) 8 8 
Number of scans 26–30 18 
Time resolution (ms) 75 75 
Total examination time (s) 45 32 
Slice acquisition (mm) 128 x 0.6* 192 x 0.6* 
Tube voltage (kV) 80 80 
Tube current (mAs) 175 180 
Dose length product (mGy × cm) ° 2,520 1,931 
Effective dose estimation (mSv) 37 33.3 
Contrast media dosage (mL) 50–60 50–60 
Flow rate (mL/s) 6 6 
Contrast media Iomeron®, Bracco Imaging SpA, 
Milan, Italy 
Iomeron®, Bracco Imaging 
SpA, Milan, Italy 
Iodine concentration (mg/ml) 300 300 
*Using the z-flying focal spot; °conversion factor k = 0.015 mSv/(mGy × cm). 
	
Routine follow-up examinations (CT or MRI) performed to assess the treatments were 
not modified by the study protocol.  
The response was assessed according to EASL criteria. Patients were also subdivided 
into complete responders (no viable tumor after treatment) and incomplete responders 
(remaining viable tumor after treatment), and the latter included patients with partial 
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response, stable disease, and progressive disease as well as those patients who needed to 
undergo further DEB-TACE treatment. 
 
Quantitative perfusion analysis was performed in one center. ALP (mL/min/100 mL), 
PLP (mL/min/100 mL), and HPI (ALP/(ALP + PLP in %) maps were automatically 
calculated by the software Syngo® (CT Body Perfusion, VB10A, Siemens). Perfusion 
analyses were performed by two independent radiologists each with four years of 
experience in abdominal radiology. The circular region of interest marker was placed 
manually on the ALP map. The software copied the region of interest in the same 
position on the PLP and HPI maps. ALP, PLP, and HPI were calculated for each region 
of interest obtained, and the percentage difference from pre- to post-treatment values 
((post-value – pre-value)/pre-value × 100) were calculated for each parameter, i.e. 
ΔALP, ΔPLP, and ΔHPI. 
3.2 PAPER	II	
This was an open, dual center prospective study conducted at Uppsala University 
Hospital and Karolinska University Hospital. Patients admitted to Uppsala University 
Hospital were treated with TAI of doxorubicin-in-lipiodol emulsion without the use of 
any embolic agent, while patients treated at Karolinska University Hospital received 
DEB-TACE treatment using drug-eluting beads saturated with doxorubicin. The study 
was designed to detect a two-fold difference in the main parameter, AUC 0–7 days, for 
which a minimum of 11 patients in each group was needed 43.  
3.2.1 Inclusion	criteria	
 HCC eligible for TAI or TACE, creatinine ≤ 115 µmol/L, bilirubin ≤ 35 µmol/L, 
albumin ≥ 28 g/L, white blood cells ≥ 1.5 × 109/L, and INR ≤ 1.7. 
3.2.2 Exclusion	criteria		
Non-measurable or non-assessable HCC, portal vein thrombosis (but not thrombosis of 
a segment branch of the portal vein), extra-hepatic cancer involvement, 
contraindications to arteriography or to doxorubicin or other anthracyclines, ascites 
grades 2 or 3, pregnancy, any systemic or local infections (with the exception of HIV 
responsive to therapy, hepatitis B virus, or hepatitis C virus), prior treatment with 
doxorubicin during the last three months, and prior TAI or TACE treatment.  
3.2.3 Study	events	
Each patient was planned for four visits. Table 9 details the events taking place at each 
visit. 
 
 
 
 
 
22 
Table 9. Events tacking place at each patient visit in study II. 
VISIT EVENT 
1 • Blood sampling and baseline CT or MRI if last examination is older than four weeks 
2 • Endovascular treatment with the assigned drug-delivery system. Blood sampling for pharmacokinetic analysis and safety monitoring       
•  Collecting urine (up to 24 h) for pharmacokinetic analysis 
3 • Blood sampling for pharmacokinetic analysis and safety monitoring 
4 • Follow-up CT or MRI 
	
3.2.4 Preparation	of	the	drug-delivery	system	
TAI 
In this arm, one syringe contained the 3 mL aqueous doxorubicin solution, that is, 2.56 
mL of iohexol (Omnipaque® 300 mg I/mL; GE Healthcare, Stockholm, Sweden), 
which, in addition to being a contrast agent, acts as a densifier to stabilize the emulsion 
34, and 50 mg doxorubicin hydrochloride (Adriamycin®; Pfizer Inc., New York, NY) in 
0.44 mL of sterile water. The other syringe contained 10 mL of lipiodol (Lipiodol Ultra 
Fluide®, Guerbet, Aulnay-sous-Bois, France). The syringe contents were mixed 
manually by pumping the contents from one syringe to the other 10−15 times to get a 
homogenous doxorubicin-in-lipiodol emulsion. 
DEB-TACE 
The particles (the drug-eluting beads) were saturated with doxorubicin by mixing 2 mL 
of particles with 75 mL of doxorubicin aqueous solution (2 mg/mL; Teva Parenteral 
Medicines Inc., Irvine, California) to reach a doxorubicin concentration of 37.5 mg/mL 
embolic agent. The suspension of particles saturated with doxorubicin was delivered to 
the intervention suite as a 5 mL suspension of 2 mL particles and 3 mL supernatant. A 
mixture of the suspension consisting of particles, normal saline solution, and contrast 
media (Visipaque 270 mg/mL) at a ratio of 1:2:3 mL was injected into the tumors’ 
feeding vessel(s). 
3.2.5 The	endovascular	procedures		
The TAI and TACE procedures were performed under fluoroscopic guidance. A 5 
Charrière sheath was placed in the right common femoral artery. Catheterization of the 
coeliac trunk and the hepatic artery was carried out. The selectivity was chosen as lobar 
for TAI and superselective for DEB-TACE. Catheterization was performed with either 
a 4 Charrière catheter or an additional micro catheter. A 7 Charrière sheath was placed 
in the femoral vein, and a 5 Charrière catheter was then placed through the slightly 
coarser sheath with its pigtail in the orifice from the hepatic vein to the vena cava. Local 
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blood sampling was carried out via this pigtail catheter. The sheath in the femoral vein 
enabled access to the iliac vein for systemic blood sampling during the 6 hours after 
treatment while the catheter was still in place. The drug-delivery system (the 
doxorubicin-in-lipiodol emulsion or the suspension of drug-eluting beads saturated with 
doxorubicin) was administered slowly by hand until complete embolization was 
reached or until the intended maximum dose was infused (50 mg doxorubicin for TAI 
and 150 mg for DEB-TACE).  The individual doxorubicin dose given by TAI or DEB-
TACE was recorded. The choice of size of the drug-eluting beads/agent was based on 
the size of the vessels in the tumor in each patient. If the maximum dose of doxorubicin 
was reached in DEB-TACE but not complete stasis, particles without doxorubicin were 
injected (bland embolization) until complete stasis was accomplished. No additional 
embolization materials were used in the TAI treatment. 
3.2.6 Blood	and	urine	sampling	
Samples were collected from a peripheral vein before treatment. Blood samples were 
collected every10 min (TAI) and 15 min (DEB-TACE) after infusion start until the end 
of the infusion of the drug-delivery system. After that, samples were collected from the 
vena cava (via the catheter inserted via the left femoral vein with its pigtail adjacent to 
the orifices of the liver veins) and from the peripheral vein (femoral vein) at 0, 5, 15, 
and 30 min and 1, 2, and 6 h. The pigtail catheter inserted via the femoral vein was 
extracted after 6 h. Additional samples were collected from peripheral veins in the 
patient’s arm at 24 h and again 5–7 days after the treatment. Blood samples were 
collected in ethylenediaminetetraacetic acid-containing Vacutainers® (4 mL, BD 
Biosciences, Franklin Lakes, NJ) and centrifuged (10 min, 18°C, 3600 × g). The plasma 
was thereafter transferred to dark polypropylene tubes before storage at −20°C until 
analysis. Urine was collected directly after the treatment and over the course of the next 
24 h. The urine was weighed, and aliquots were collected in dark polypropylene tubes 
and stored at −20°C until analysis. Because doxorubicin is photosensitive, all samples 
were protected from light. 
3.2.7 Drug	analysis	and	pharmacokinetics	
A Waters Acquity UPLC® system coupled to a Quattro Ultima Pt tandem quadrupole 
mass spectrometer (UPLC−MS/MS, Waters Corporation, Milford, MA) was used for 
the drug analysis (doxorubicin and its metabolite doxorubicinol). Noncompartmental 
analysis using Phoenix WinNonLin 6.3 was performed to assess concentration–time 
profiles for doxorubicin and doxorubicinol. Because the pharmacokinetics of 
doxorubicin is linear 76, the in vivo pharmacokinetic parameters – AUC and maximum 
concentration (Cmax) for TAI and DEB-TACE – were dose-normalized (to make the 
parameters comparable) according to the equation: 
 𝐷𝑜𝑠𝑒 − 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑑𝑜𝑠𝑒  𝑋100 
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3.2.8 Adverse	events	
Expected serious adverse events requiring additional treatment included liver failure, 
hepatic abscess formation, and cholecystitis or other life-threatening events. The 
expected doxorubicin-related events from these were alopecia and renal failure. The 
expected TAI/TACE-related events included post-embolization syndrome (nausea, 
pain, and fever), alopecia, renal failure, and liver failure. Monitored blood tests included 
serum bilirubin, C-reactive protein (CRP), alanine amino transferase (ALAT), aspartate 
amino transferase (ASAT), alkaline phosphatase, prothrombin-INR, blood count, serum 
albumin, serum creatinine, blood urea, blood sodium, and blood potassium. 
3.2.9 Response	assessment	
For the TAI group, an MRI (using a routine clinical liver protocol) was conducted 4 
weeks after the endovascular treatment. For the DEB-TACE group, a CT (using a 
routine clinical liver protocol) was conducted 4 weeks after the endovascular treatment. 
Response was assessed according to the mRECIST criteria. 
 
3.3 PAPER	III	
This was a retrospective, observational, single center study conducted at Karolinska 
University Hospital in a real-life setting to compare survival and adverse events of 
cTACE with DEB-TACE. Patients treated with either cTACE or DEB-TACE during 
the period January 2004–January 2013, were included. A search for ICD-10 code C220 
(liver cell carcinoma) and the intervention registry code PCT20 (transarterial 
chemoembolization) in our database was conducted. Patients who had received both 
treatments as well as those who underwent local ablation or liver resection post TACE 
were excluded from the analysis of overall survival. Survival days were counted from 
the time of the first TACE treatment until death or censoring. Reasons for censoring 
were liver transplantation or end of follow-up (28 Nov. 2016).  
Only the adverse events after the first TACE were evaluated. Patients with inadequate 
documentation or incomplete procedures were excluded from the analysis. The patient 
charts were searched for abdominal pain, nausea and vomiting, fever, fatigue, bleeding 
at the access site, infection, ascites, bilirubin increase, hepatic encephalopathy, and liver 
abscess within one week after each treatment. Table 10 lists necessary definitions of  
some of the retrieved data.  
The factors of age (years), sex (male), BMI (kg/m2), diabetes, liver function, tumor 
characteristics, and given treatment (cTACE or DEB-TACE) were studied in the 
univariate analysis. 
Factors that had a significant effect on survival were included in a multivariate analysis 
together with factors known or suspected to affect mortality (sorafenib treatment, 
bilobar disease, extrahepatic spread of HCC, macroscopic vessel growth, increased 
ECOG score, increased Child–Pugh class, and alcohol overconsumption). 
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Table 10. Definitions of some data that was extracted from patients’ records	
DATA Definition 
Smoking Current or former smoker / never smoked 
Body	mass	index Calculated as weight [kg] / height2 [m] 
Alcohol overconsumption 1. A diagnosis of alcoholic liver disease or statement of alcohol 
overconsumption in patient charts 
2. An alcohol intake >30 grams per day (or 14 units per week) for males or >20 
grams per day (or 10 units per week) for females  
Alcohol moderate consumption An intake below overconsumption but ≥ one unit per week 
No alcohol consumption Neither moderate nor overconsumption. 
Diabetes mellitus type 2 A registered diagnosis in patient charts or a registered prescription of any anti-
diabetic medication 
Hypertension A registered diagnosis in patient charts or a registered prescription of any anti-
hypertensive medication  
Cardiovascular disease A registered diagnosis (ischemic heart disease, cardiac myopathy, stroke, heart 
failure, arrhythmia, and coronary valve disease) but not hypertension alone 
 
Liver cirrhosis A registered diagnosis (biopsy verified, based on elastography >15 kPa) or 
based on imaging findings 
 
 
3.3.1 The	endovascular	procedure	
Doxorubicin-in-lipiodol emulsion was injected superselectively or segmentally until a 
high grade of stasis or a maximum dose of 50 mg doxorubicin was reached when 
performing cTACE. Then a suspension of contrast and fragments of Gelfoam sponge 
(with a size of aproximatly1 millimeter) were injected to increase the degree of stasis. 
DEB-TACE was performed superselectively as a rule, otherwise it was performed 
segmentally. The DEB-TACE treatment was stopped when either complete stasis or a 
maximum doxorubicin dose of 150 mg was reached. When the maximum doxorubicin 
dose was reached but not complete stasis, particles (unsaturated with doxorubicin) of 
larger size were injected to reach complete embolization. 
3.3.2 Response	assessment	
CT scans (using a routine clinical liver protocol) were carried out 4 weeks after each 
treatment, and the response was assessed according to WHO, EASL or mRECIST 
criteria depending on the preference of the evaluating radiologist at the time of 
treatment. The follow-up CT was presented at a multi-disciplinary conference where the 
decision to continue follow-up or to offer the patient a new DEB-TACE was made. 
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3.4 PAPER	IV	
This was a randomized controlled trial conducted at Karolinska University Hospital. 
Patients were randomized at 1:1 ratio to receive either TAE using polyvinyl alcohol 
particles as an embolic agent (Biocompatibles UK Ltd, Surrey, United Kingdom) or 
DEB-TACE using the same embolic agent saturated with doxorubicin.  
3.4.1 Inclusion	criteria		
Adults of both genders with biopsy-verified RCC less than 7 cm in diameter and 
eligible for nephron-sparing surgery or radical nephrectomy.  
3.4.2 Exclusion	criteria		
Known hypersensitivity to doxorubicin, pregnancy, recent myocardial infarction (within 
the last 6 months), glomerular filtration rate < 45 mL/min, and intratumoral 
arteriovenous shunts detected on subtraction angiography performed before 
superselective embolization of the vessels feeding the tumors.  
3.4.3 Determination	of	the	size	of	the	embolic	agent	(drug-eluting	beads)	
Because the particles used in DEB-TACE are available in different sizes, a reproducible 
methodology to determine the size of the particles for each tumor was needed. Figure 9 
illustrates how the size of the particles used was determined.  
  
Figure 9. A diagram showing how the size of the particles was determined in study IV. 
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3.4.4 The	endovascular	procedure	
A 5 Charrière sheath was placed in the right femoral artery after administration of 1% 
Lidocaine® (10 mg/mL; AstraZeneca AB, Södertälje, Sweden). A 5 Charrière Contra 2 
catheter (Boston Scientific Limited, Galway, Ireland) was used to catheterize the renal 
artery under fluoroscopic guidance (figure 10). Intratumoral arteriovenous shunts were 
excluded by manual injection of 10–20 mL iodixanol (Visipaque® 270 mg/mL; GE 
Healthcare, Oslo, Norway). The vessel feeding the tumor was catheterized using a 2.7 
Charrière microcatheter (Boston Scientific Limited, Cork, Ireland) (figure 11). A 
mixture of the suspension of particles, normal saline solution, and contrast media 
(Visipaque 270 mg/mL) at a ratio of 1:2:3 mL was injected under fluoroscopic guidance 
until complete stasis in the feeding vessels was obtained or when a maximum dose of 
140 mg doxorubicin was reached. If the maximum doxorubicin dose was reached 
without complete stasis, bland embolization using particles that were one size larger 
was performed until complete stasis was reached. 
 
 
 
 
 
 
Figure 10. A subtraction angiography image showing the placement of the guiding catheter in the renal 
artery and contrast enhancement in the left kidney. Notice the round RCC laterally in the upper pole and 
its feeding vessel. 
 
 
28 
 
Figure 11. A subtraction angiography image showing the placement of the microcatheter in the tumor’s 
feeding vessel and contrast enhancement only in the tumor. 
 
3.4.5 Safety	assessment	
All patients were observed for one day after endovascular treatment. Vital signs and 
routine blood tests (blood hemoglobin, plasma potassium, plasma sodium, CRP, 
leukocyte count, and plasma creatinine) were assessed before and after endovascular 
treatment, before follow-up CT, and before surgical resection. 
Prothrombin time, INR, and platelet count were assessed before endovascular 
treatment. Pain was evaluated in the intervention suite according to the visual analog 
scale (VAS) after endovascular treatment. During the patient´s stay at the urology ward, 
pain was also assessed when the patient complained of pain and every half hour after 
analgesia administration until pain relief was reached. Complications were evaluated 
according to the Society of Interventional Radiology (SIR) classification system 77. 
3.4.6 Response	assessment	
The CT scan performed before treatment was considered as a baseline CT examination. 
The response was evaluated according to mRECIST on CT 4–6 weeks after the 
treatments. Necrosis in the excised tumor was also evaluated by light microscopy using 
the same measuring methodology used for mRECIST. Because the observation time 
was short (4 weeks), the commonly used term “stable disease” was replaced by the term 
“no response”. The terms “complete response”, “partial response”, and “progressive 
disease” were used unaltered. A dual-source 64-row SOMATOM Definition Flash 
(Siemens Healthcare, Forchheim, Germany) or a 64-row GE LightSpeed VCT XT (GE 
Healthcare, Milwaukee, Wisconsin) CT scanner was used for all CT examinations. 
Follow-up CT scans included non-contrast phase, late arterial phase, parenchymal 
phase, and excretory phase imaging. The startup time for the phase with contrast media 
was determined by using a bolus-tracking technique that places the marker for the 
triggering region of interest in the abdominal aorta. The startup time for the late arterial 
phase was set at a 20-second post-threshold value of 160 HU. An additional 50 seconds 
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was added for parenchymal phase imaging. Excretory phase imaging was conducted 
460 seconds after parenchymal phase imaging. After surgery, all surgical specimens 
were immediately fixed and embedded in paraffin wax. The specimens were reviewed 
according to a routine protocol using light microscopy. Necrosis was quantified 
histopathologically similarly to the mRECIST measurements by dividing the largest 
remaining viable tumor diameter by the largest tumor diameter multiplied by 100. The 
remaining viable tumor mass was marked with a pen under the light microscope, as was 
the pseudo capsule of the tumor, enabling diameters to be measured. 
3.4.7 Surgery	
Nephron-sparing surgery or nephrectomy was performed laparoscopically or with open 
surgery depending on the anatomical characteristics of the tumor and the preference of 
the operating surgeon. 
 
3.5 STATISTICS	
Data were tested for normal distribution using the Shapiro–Wilk test. Data were 
expressed as means ± SD or medians ± ranges. Intraclass correlation coefficients (ICCs) 
were used for determining the inter-reader agreement. ICC below 0.69 was defined as 
poor, between 0.70 and 0.79 as fair, between 0.80 and 0.89 as good, and above 0.9 as 
excellent. Bland–Altman analysis was used to assess the inter-reader agreement. 
Fisher’s exact test (binomial ordinal values), chi2-tests (polynomial ordinal values), or 
independent samples t-tests (numeric values) were used to test for significant 
differences. The Mann–Whitney U-test was used to test for significant differences when 
data were not normally distributed. The Wilcoxon signed rank test was used for non-
parametric data. Student´s t-test was used to test for significant difference when data 
were normally distributed. Spearman correlation for ordinal variables was performed in 
order to assess relations between parameters. Receiver operation characteristics (ROC) 
analysis with area-under the curve (AUC) calculation was performed to estimate the 
accuracy of the quantitative assessment.  
Cox regression models were used to estimate hazard ratios for overall survival. Kaplan–
Meier statistics were used to calculate survival curves, which were tested by log-rank 
test for significant differences in paper III. IBM SPSS Statistics for Mac Version 22; 
release 22.0.0.1 (IBM Corp®, Armonk, New York) and IBM SPSS Statistics, Version 
23.0 (SPSS Inc.®, Chicago, IL) were used for all calculations. 
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4 RESULTS	
 
4.1 PAPER	I	
Out of 24 included patients, 21 (88%) had one HCC treated by DEB-TACE. The other 
3 patients (12%) had two HCCs treated at the same session, of which only the largest 
HCC was included in the analysis. The mean size of the included HCC before and after 
DEB-TACE was 27 ± 11.9 mm (range 14–55 mm). 
Routine follow-up examinations to assess the treatments’ effects were performed in 22 
patients using multi-phase contrast-enhanced CT (n = 12) or MRI (n = 10), and 2 
patients were lost to follow up. The mean imaging follow-up time was 47 ± 22 days 
(range, 24–90 days). 
Evaluation according to EASL criteria showed 7 patients with complete response 
(29%), 9 patients with partial response (38%), and 6 patients with progressive disease 
(35%). Regarding presence or absence of response, 7 were classified as complete 
responders (29%) and 15 as incomplete responders (63%). Interreader agreement was 
fair to excellent (ICC, 0.716–0.942).  
Monitoring of blood perfusion of HCC before DEB-TACE treatment for both pre-
treated and non-treated lesions showed that; 
- Previously DEB-TACE–treated lesions showed a mean ALP of 33.5, PLP of 
29.9, and HPI of 63.49, whereas non-treated lesions (lesions never treated in the 
past) showed a mean ALP of 43.77, PLP of 11.5, and HPI of 82.09. 
- PLP of pre-treated lesions (n = 12) was significantly higher (p = 0.01) than non-
treated lesions (n = 20), whereas no significant difference was seen in ALP or 
HPI.  
 
Comparing blood perfusion of HCCs before DEB-TACE to after DEB-TACE 
 
- There was a significant increase in PLP (+17%) and a significant decrease in 
ALP (−53%) and HPI (−25%) after DEB-TACE treatment (each p < 0.05). 
Outcome prediction 
- None of the perfusion parameters before DEB-TACE showed a significant 
correlation with EASL response grades. 
- No significant difference in PLP was seen for non-treated lesions only (mean 
17.5 vs. 8.9 mL/min/100mL; p = 0.19). All other parameters were similar 
between non-treated and treated (all, p > 0.05). 
- PLP before DEB-TACE treatment was significantly higher in complete 
responders (mean 24.6 vs. 9.3 mL/min/100mL; p < 0.05) for all lesions. ROC 
analysis (figure 12) showed an AUC for PLP for predicting treatment response 
of 0.762 (95% confidence interval; 0.535–0.989). Using a cutoff HPI value of 
43%, we found a sensitivity of 100% and specificity of 66% for predicting 
response to DEB-TACE. 
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Early DEB-TACE response assessment  
- Both HPI (r = 0.48; p = 0.02) and ΔALP (r = 0.45; p = 0.04) early after DEB-
TACE correlated significantly with EASL response grades (complete response, 
partial response, stable disease, and progressive disease).  
- HPI after DEB-TACE was significantly lower in complete responders (33% vs. 
non-complete responders 52%; p < 0.05). ROC analysis showed an AUC for 
HPI in detection of incomplete response of 0.795 (95% confidence interval: 
0.597–0.994). To obtain a 100% sensitivity for detection of incomplete 
response, a cut-off HPI of 51% or higher was necessary, resulting in a 
specificity of 60%. 
 
 
 
Figure 12. Receiver operating characteristic (ROC) analysis of PLP before DEB-TACE for 
prediction of treatment response and HPI after DEB-TACE for detection of residual tumor. 
 
 
4.2 PAPER	II	
Thirteen patients received TAI (11 men and 2 women; mean age 69 years, range 55–83 
years; and mean tumor size 62 mm, range 30–130 mm) and 12 patients received DEB-
TACE (9 men and 3 women, mean age 73 years, range 53–85 years, and mean tumor 
size 36 mm, range 6–65 mm). Two patients in the TAI group were withdrawn because 
of severe liver failure after the treatment (one patient died). One patient from the same 
group did not attend the follow-up MRI, leaving 9 patients for response assessment in 
the TAI group. One patient in the DEB-TACE group did not attend the CT follow-up 
leaving 11 patients for response assessment. For the pharmacokinetic analysis, 11 
patients from each group were included (figure 13). 
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All patients in the TAI group received 50 mg doxorubicin. The mean infusion time was 
10 min (range 2.0–50 min). The terminal half-life (5–7 days) of doxorubicin was 
similar to that of doxorubicinol, which was 54 ± 8 h. Doxorubicin had a 2-fold longer 
half-life after 5–7 days in the DEB-TACE group. 
Patients in the DEB-TACE group received different doses of doxorubicin depending on 
the size and the vascularity of the treated tumor.	The mean administered dose was 83 
mg (range 22.5−150 mg). The mean infusion time was 13 min (range 3.0–34 min). The 
terminal half-life at 5−7 days was slightly shorter for doxorubicin than for 
doxorubicinol (99 ± 99 h and 120 ± 53 h, respectively).  
 
 
Figure 13. A diagram showing the flow of patients through study II.  
 
 
The plasma concentration–time profiles and pharmacokinetic parameters for TAI and 
DEB-TACE were compared after normalizing. The maximum plasma doxorubicin 
concentration for TAI was 8-fold higher than for DEB-TACE (960 vs. 110 ng/mL, 
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respectively, p < 0.001). The mean AUC (0–24 h) values were 4-fold higher in TAI 
compared to DEB-TACE (540 vs. 140 h·ng/mL, p < 0.0001).  
AUC (0−5 days) for both doxorubicin and doxorubicinol was significantly higher with 
TAI as was AUC (0–7 days) (p < 0.05, p < 0.01 respectively). AUC (0−7 days) was 
higher, although not significantly, in the TAI group. 
Analysis of samples obtained from the vena cava at the level of the orifices of the 
hepatic veins showed that the plasma exposure to doxorubicin and doxorubicinol was 
higher in TAI compared to DEB-TACE (630 vs. 140 h·ng/mL and 130 vs. 15 h·ng/mL, 
respectively, p < 0.0001). The individual ratios of local to systemic plasma doxorubicin 
concentrations directly after administration (time 0) were 1.57 ± 0.63 and 1.21 ± 0.14 in 
the TAI and DEB-TACE groups, respectively. This difference lessened with time and 
stabilized at 15–30 min to around 1.1–1.2 in both groups. The remaining dose of 
doxorubicin remaining in the liver after 6 h was about 1.8 times higher in DEB-TACE 
(p < 0.001). 
4.2.1 Safety		
There were no statistically significant differences regarding the monitored safety 
parameters between the treatment groups. In some patients, the ASAT and ALAT 
concentrations were more elevated at 24 h post-treatment in the TAI group compared to 
the DEB-TACE group. However, after 5−7 days the elevated ASAT and ALAT 
concentrations were approaching their baselines again. The increase in CRP did not 
differ between the two groups. 
In the TAI group, four patients out of 13 (31%) suffered from treatment-induced 
postembolization syndrome. Two patients (15%) suffered from liver failure, and one of 
them (8%) suffered later from circulatory arrest. These events led to patient withdrawal 
from the study. Other documented events were rectal bleeding (n = 1, 8%), bleeding 
from the venous access site (site for catheter placement) (n = 1, 8%), confusion (n = 1, 
8%), and headache (n = 1, 8%). No other events were reported in this group. 
In the DEB-TACE group, four patients (33%) developed postembolization syndrome 
(either demanding or not demanding treatment), one patient (8%) had small gas bubbles 
in the treated lesion, which were considered to be due to infection, two patients (17%) 
had back pain, and one patient (8%) had a urinary tract infection. No other events were 
reported in this group. 
4.2.2 Response	assessment	
Response to treatment was assessed using CT or MRI before and at 4–6 weeks after the 
endovascular treatment (TAI or DEB-TACE) according to the mRECIST criteria. 
Tumor responses are presented in Table 11. The overall response (CR and PR 
combined) was 91% (n = 10/11) for DEB-TACE and 67% (n = 6/9) for TAI. 
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Table 11. Treatment Responses According to mRECIST 
mRECIST TAI DEB-TACE 
PD 0 (0 %) 1 (9.1%) 
SD 3 (33 %) 0 (0%) 
PR 5 (56 %) 8 (73 %) 
CR 1 (11 %) 2 (18 %) 
PD=progressive disease, SD= stable disease, PR= partial response, CR= complete response. 
4.3 PAPER	III	
The flow of patients through this study is shown in figure 14. The database search 
revealed 215 patients treated with cTACE or DEB-TACE between January 1st, 2004, 
and January 15th, 2013. Thirteen patients were excluded due to inadequate 
documentation or incomplete treatment. Adverse effects were evaluated in 202 patients 
after the first treatment. The overall survival analysis was performed on 179 patients 
because another 14 patients were excluded from this analysis because of receiving both 
treatments (during the period the center switched from cTACE to DEB-TACE). 
Another 9 patients were excluded due to surgical resection or thermal ablation after 
cTACE or DEB-TACE. Median follow-up was 7.1 years (range 3.8-12.1). 
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Figure 14. A chart showing the enrolment of patients through study III. Adverse events were evaluated 
after the first TACE procedure on 202 patients, and overall survival was calculated for 179 patients 
who received either cTACE or DEB-TACE treatment, respectively. 
 
Patients in the DEB-TACE group were older and had a higher number of tumors 
(p<0.05) compared to those in the cTACE group. There was a larger proportion of 
patients having BCLC-class C in the in the cTACE group, partially due to 
macrovascular invasion or extrahepatic spread, compared to the DEB-TACE group 
(p<0.05). Underlying etiologic diagnosis, presence of liver cirrhosis, Child-Pugh class 
and ECOG performance status did not differ significantly between the two groups. 
As for the treatment characteristics of the patient cohort evaluated for survival (n=179), 
the mean time from diagnosis to start of TACE treatment was 5 days shorter, and the 
number of treatment sessions was higher, in the DEB-TACE group (p<0.05). Pre-
TACE ablation was more common in the cTACE group compared with the DEB-TACE 
group. 
The adverse effects (abdominal pain, nausea and vomiting, fever, and fatigue) were 
significantly less common in patients treated with DEB-TACE compared to cTACE (p 
< 0.05). However, there was no significant difference in the frequency of serious 
complications such as intra abdominal bleeding, sepsis, ascites, or jaundice (p = 0.15). 
Bleeding from the puncture site (the vascular access) was less common in the DEB-
TACE group (p < 0.05). Ascites, increase in bilirubin, infection, encephalopathy, and 
post-treatment abscess were similarly frequent after the endovascular treatments in the 
two groups.  
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Median overall survival did not differ significantly between the two treatments (17.1 
months and 19.9 months for cTACE and DEB-TACE group respectively). 
Total tumor size and increased number of tumors predicted decreased overall survival 
in the univariate analysis. In the multivariate analysis, adjusted hazard ratios 
demonstrated that only tumor size, and portal vein thrombosis were associated with 
decreased overall survival while sorafenib treatment after TACE with increased overall 
survival. 
Figure 15 demonstrates similar all-cause mortality for the first five years of follow-up 
between patients treated with DEB-TACE as compared to cTACE (log-rank test p= 
0.33). 
 
 
Figure 15. Kaplan–Meier survival curve for the first 5 years separated into cTACE and DEB-TACE 
groups (log rank p = 0.33). 
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4.4 PAPER	IV	
Between 2012 and 2015, 12 patients (5 men and 7 women, age 66 years ± 9.8) were 
recruited. Mean tumor size was 3.2 cm ± 0.62. Figure 16 shows the flow of enrollment. 
 
Figure 16. A diagram showing the flow of patients through study IV. 
 
There was no significant difference between the DEB-TACE group and the TAE group 
in age (p = 0.17) or tumor size (p = 0.52). Only one tumor was Fuhrman grade 1, and all 
other tumors were Fuhrman grade 2. Subtraction angiography showed no intratumoral 
arteriovenous shunts. All patients were treated superselectively until complete stasis 
was reached. Patients in both arms were treated with particles 100–300 µm in size 
except for one patient in the DEB-TACE arm who was treated by 100–300 µm particles 
in the tumors’ main feeding artery and 75–150 µm particles in a polar artery. The same 
patient was treated again, on request and outside the protocol, because of aggravated 
Parkinson disease that made the patient unfit for either surgery or ablation. This patient 
was identified as 11a for the first DEB-TACE and as 11b for the second treatment. 
4.4.1 Pain	assessment	
In the TAI group one patient reported pain at the puncture site in the right groin (VAS 
4) during closer device deployment in the intervention suite. All other patients reported 
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discomfort at the puncture site graded VAS 1 or 2. Two patients developed flank pain 
during the first 24 hours after allocated treatment and while still on the urology ward, 
both graded as VAS 3. All patients in this group were discharged the day after TAE 
treatment. 
In the DEB-TACE group, all patients reported discomfort at the puncture site graded 
VAS 1 or 2. Three patients in this group developed flank pain during the first 24 hours 
after allocated treatment, graded as VAS 3, 5, and 6. Patient 11 had nausea and transient 
fever (38 C°) after the second DEB-TACE procedure. All patients in this group were 
discharged the day after the endovascular treatment. 
4.4.2 Post	treatment	blood	tests	
There was a significant increase in leukocyte count (p = 0.01) and a non significant 
elevation of CRP in the DEB-TACE group. An initial plasma creatinine elevation from 
65 to 80 µmol/L was observed in patient 11 after the second DEB-TACE. Patient 11’s 
plasma creatinine had normalized 4 weeks later. 
All blood tests were normal after the allocated treatment, before follow-up CT, and 
before surgery. No patient had major complications according to SIR classification of 
complications. 
4.4.3 Surgery	
In the DEB-TACE group, Patient 11 was disqualified for surgery (as previously 
mentioned). Patient 7 declined surgery and chose surveillance after being informed that 
a complete response was observed on CT evaluation. Local tumor recurrence was 
identified on CT in this patient 26 months later, and the patient was scheduled for 
operation. Therefore 10 patients out of 12 underwent surgical exploration. Of these, 
eight had nephron-sparing surgery and one had nephrectomy. One patient in the TAE 
group did not have the tumor removed (abandoned surgery due to multiple peritoneal 
metastases from a gastrointestinal stromal tumor, which complicated the surgery). 
4.4.4 Response	assessment	
Patient 2 in the TAE group declined to undergo CT evaluation after endovascular 
treatment. Patient 11 did not proceed to surgery due to deterioration in performance 
status and received, on request, a second DEB-TACE. In this patient, necrosis increased 
from 70% to 100% after the second DEB-TACE procedure. Because the second DEB-
TACE was outside the study protocol, the necrosis assessment was excluded from all 
statistics. Infarcted renal tissue was observed adjacent to the treated tumor on follow-up 
CT in all patients (figure 17 and 18). These infarcted areas were seen on angiography 
sharing blood supply with the tumors. 
Tables 12 and 13 show the results of CT evaluation according to mRECIST and the 
percentage of necrosis seen on CT and on microscopy. CT showed that patients in the 
DEB-TACE group (n = 6) had significantly (p = 0.018) higher degree of necrosis 
compared to TAE (n = 5). The histopathologic evaluation showed similar results (p = 
0.016). Percentage of necrosis seen on microscopy correlated significantly (p = 0.0005) 
with the radiological findings (n1 = n2 = 4).  
 
   39 
 
Table 12. Patient Characteristics, Tumor Size, and Results in the TAE group 
Participan
t 
Gende
r 
Age 
(year
s) 
Tumor 
size 
(cm) 
Biopsy 
report 
mRECIST Necrosis 
shown on 
CT (%) 
Necrosis shown 
on microscopy 
(%) 
Size of DEB(µm) ECOG 
2 M 55 3.0 RCC F2 - - 0 100-300 1 
3 M 69 3.0 RCC F2 NR 0 0 100-300 2 
4 F 48 3.0 RCC F2 PR  77 50 100-300 1 
5 F 74 3.0 RCC F1 NR 0 20 100-300 1 
8 F 68 3.5 RCC F2 NR 0 - 100-300 2 
9 M 64 3.0 RCC F2 PR  70 60 100-300 0 
Abbreviations: M = male, F = female, RCC F = Renal Cell Carcinoma Fuhrman, mRECIST = modified Response Evaluation Criteria 
in Solid Tumors. PR = partial response, NR = no response. ECOG= Eastern Cooperative Oncology Group score for performance 
status. 
 
Table 13. Patient Characteristics, Tumor Size, and Results in the DEB-TACE group 
Participan
t 
Gen
der 
Age 
(Years) 
Tumor 
size 
(cm) 
Biopsy 
report 
mRECIST Necrosis 
shown on 
CT (%) 
Necrosis shown 
on microscopy 
(%) 
Size of DEB(µm) ECOG 
1 M 62 2.0 RCC F2 CR 100 95 100-300 1 
6 F 52 3.0 RCC F1 PR 90 95 100-300 1 
7 F 77 3.5 RCC F2 CR 100 - 100-300 3 
10 M 69 3.0 RCC F2 PR 80 80 100-300 1 
11a F 77 4.5 RCC F2 PR 70 - 75-150, 100-300 3 
11b F 77 4.0 RCC F2 CR 100 - 75-150, 100-300 3 
12 F 74 4.0 RCC F2 PR 90 80 100-300 2 
Abbreviations: 11a = participant 11’s first TACE, 11b = Participant 11’s second TACE, M = male, F = female, RCC F = Renal Cell 
Carcinoma Fuhrman, mRECIST = modified Response Evaluation Criteria in Solid Tumors, CR = complete response, PR = partial 
response. ECOG = Eastern Cooperative Oncology Group score for performance status. 
The necrotic areas seen on microscopy were too small to be outlined by a pen and were 
scattered on the specimen slides from patient 3; therefore, the maximum diameter of the 
tumor was unchanged and the percentage of necrosis was zero when evaluated by 
microscopy. For similar reasons, the RCC in patient 5 had an unchanged diameter after 
TAE, whereas microscopy showed 20% necrosis. On the other hand, even when no 
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remaining tumor region could be detected on CT, some isolated individual viable tumor 
cells could be identified using light microscopy. 
 
 
 
Figure 17. Images of RCC treated by TACE in patient 12. (a) Subtraction angiography image obtained after selective catheterization 
of the left renal artery showed contrast-filled intratumoral vessels (arrowhead) before TACE. (b) Subtraction angiography image 
obtained during TACE showed no contrast-filled vessels in the center of the tumor owing to ongoing embolization. The area adjacent 
to the RCC (arrowhead) shares its blood supply with the tumor. (c) CT image obtained before TACE showed contrast enhancement 
in the RCC (arrowhead). (d) CT image obtained 4 weeks after TACE showed no contrast enhancement in the RCC (arrowhead). 
Infarcted renal tissue (arrow) is adjacent to the treated tumor. 
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Figure 18. Images of RCC treated by TAE in patient 5. (a) Subtraction angiography image obtained after selective catheterization of 
the left renal artery showed contrast-filled intratumoral vessels (arrowhead) before TAE. (b) Subtraction angiography image obtained 
during TAE showed no contrast-filled vessels in the tumor (arrowhead) owing to ongoing embolization. (c) CT image obtained 
before TAE showed contrast enhancement in RCC (arrowhead). (d) CT image obtained 4 weeks after TAE showed persistent 
contrast enhancement in RCC (arrowhead). Infarcted renal tissue (arrow) is adjacent to the treated tumor. 
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5 DISCUSSION	
The results of this project suggest that DEB-TACE is an effective and well-tolerated 
treatment for unresectable HCC. Monitoring the changes in HCC hemodynamics after 
DEB-TACE and studying the drug-delivery performance of the drug-eluting embolic 
agent might have provided answers to questions asked or discussed by interventionists 
performing DEB-TACE. DEB-TACE has been tried for the first time to treat RCC and 
the results seem promising.  
5.1 PAPER	I	
Previous perfusion CT studies have shown that HCC is characterized by a high arterial 
and low portal perfusion25. The results of this study confirm that HCC has a high 
arterialization before DEB-TACE. The mean HPI in previously treated HCC was lower 
than in non-treated (63% and 82% respectively). One of the interesting findings that 
was shown by this study was that the HPI in previously treated lesions was lower not 
due to decreased in ALP but due to an increase in PLP in these lesions. This might lead 
to the assumption that portal supply can help the HCC to survive a DEB-TACE 
procedure. 
A measurable trace of ALP was detected in most cases directly after DEB-TACE 
although the fluoroscopy and subtraction angiography had shown complete stasis. The 
question of whether this was caused by revascularization (reperfusion) or was due to the 
inaccuracy of fluoroscopy and subtraction angiography merits further studies with a 
different design.  
The very low arterial blood flow shown by perfusion CT after DEB-TACE might have 
the advantage of allowing the doxorubicin released from the particles to perfuse into the 
tumor tissue leading to the extensive tumor necrosis obtained after DEB-TACE 78. The 
decrease in ALP occurred together with an increase of PLP early after DEB-TACE and 
might have been due to changes in pressure gradient, i.e. lower arterial input might 
allow an increase of the portal input, which was suppressed by the high arterial input 
before DEB-TACE. Researchers have found that neovascularization progresses while 
portal venules diminish during HCC carcinogenesis 79. 
In established HCC, portal vessels are believed to be absent or to be responsible for 
venous drainage in the presence of a fibrous tumor capsule 80. Therefore, the increase in 
PLP might be explained either by blood perfused from surrounding sinusoids toward 
the tumor 81 or by reversed blood flow from preserved portal venules, which previously 
(prior to DEB-TACE) drained the HCC.  
Using perfusion parameters before DEB-TACE and the %-difference in perfusion 
parameters (before and after the treatment) did not enable the prediction of complete 
tumor necrosis, which is the aim of the DEB-TACE treatment and is the most important 
parameter for treatment efficacy. However, to the best of our knowledge our study was 
the first to demonstrate that perfusion CT performed early after the DEB-TACE 
treatment might allow early assessment of treatment response.  
The limited number of recruited patients and the lack of survival data are two important 
factors that have to be acknowledged. Further, larger studies are needed to refine the 
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proposed PLP and HPI cut-off values that can be used for outcome prediction and early 
response assessment. Different interventional radiologists performed the DEB-TACE 
procedures in this dual center study, but both centers used the same standards when 
applying DEB-TACE. The fact that performing perfusion CT exposes the patient to 
higher radiation dose limits this technique to oncological use in elderly patients.  
5.2 PAPER	II	
As described in the introduction section, there are two clinically used drug-delivery 
systems of doxorubicin, doxorubicin-in-lipiodol emulsion and drug-eluting beads 
saturated with doxorubicin. To the best of our knowledge, this study was the first study 
to monitor and compare their pharmacokinetics. It was shown that doxorubicin is 
released faster and exposes a larger liver volume in TAI using doxorubicin-in-lipiodol 
emulsion than in DEB-TACE using drug-eluting beads. This fast release and the 
exposure of a larger liver volume led to more and faster enzymatic conversion to 
doxorubicinol.  
Like many other studies dealing with drug pharmacokinetics, this study contained a 
limited number of participants; therefore, effect and safety data should be interpreted 
with caution. The 2-fold longer half-lives after 5–7 days for doxorubicin when given in 
DEB-TACE was due to a slower drug release rate from particles than from 
doxorubicin-in-lipiodol emulsion. The similar half-life after 5–7 days for doxorubicin 
and doxorubicinol clearly indicates that the pharmacokinetics of doxorubicinol is 
limited by its formation rate because it is a metabolite of doxorubicin. 
The mean dose-normalized AUC values in the TAI group in this study were 3.3 to 4.9-
fold lower compared to historic data presented by Johnson and colleagues 39 despite the 
fact that they used a similar dose of doxorubicin. The difference in AUC might be 
explained by differences in the physical stability of the emulsions because Johnson and 
colleagues used an emulsion that contained a 2:5 volume ratio of lipiodol and aqueous 
doxorubicin solution with normal saline, while we used an emulsion with a 3.3:1 
volume ratio that has been reported to be more stable31, 39, 76, 82. In other words, our 
study confirmed that the emulsion we used was more stable. 
The particles used to treat the DEB-TACE group in this study (size range 70−700 µm) 
generated a mean dose-normalized Cmax and AUC of doxorubicin that were consistent 
with data previously reported for DEB-TACE 500−700 µm 38. However, Varela and co-
workers reported a lower AUC0−7 days for doxorubicin of 662.6 ± 417.6 min·ng/mL 
from DEB-TACE 500−700 µm following a mean dose of 128 mg 37. Varela’s AUC 
value is 65 times lower than our dose-normalized mean (AUC0−7d 43,200 
min·ng/mL), a disagreement that can not be explained by the dose difference (100 mg 
vs. 128 mg). It might be that an accidental error was made in the units for their AUC. If 
their result were in h·ng/mL but reported by mistake as min·ng/mL, then their AUC 
values would be similar to ours. 
It is important to mention that the doxorubicin release from the drug-eluting particles is 
not homogeneous, partly because of the differences in the sizes of particles used in 
different patients, and partly because embolization prevented us from giving a 
predetermined doxorubicin dose. Researchers have found that smaller drug-eluting 
beads allow higher doses and that both correlate with higher plasma exposure of 
doxorubicin and as a result higher exposure to doxorubicinol 31. A higher doxorubicin 
release rate obtained from smaller particles, which was observed in vitro, was explained 
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by the shorter diffusion pathway (i.e. particle diameter) combined with the larger total 
surface area (higher number of smaller particles than the number of larger particles 
needed to reach stasis) than a larger drug-eluting bead 83.  
The local doxorubicinol-to-doxorubicin AUC ratio was 2-fold higher following TAI 
treatment than following DEB-TACE treatment (p < 0.001). This difference in ratio 
between the two formulations might be explained by a difference in their distribution of 
doxorubicin because the emulsion is injected into the lobe artery and spread over the 
whole lobe. The local bioavailability values for doxorubicin obtained after 6 h suggest 
that 51% of the injected doxorubicin reached the blood stream versus only 12% for the 
same period in DEB-TACE. This finding supports that the particle saturated with 
doxorubicin has a more localized and slower drug release compared to the doxorubicin-
in-lipiodol emulsion. The static environment caused by embolization is likely to restrict 
a large portion of doxorubicin from reaching the blood stream. This might explain why 
the adverse effects are milder after DEB-TACE and why two patients in the TAI arm 
suffered from liver failure after TAI but there were no such events after DEB-TACE.  
In the TAI group, two patients suffered from serious liver failure and one of them died, 
while no patient suffered from sever adverse effects in the DEB-TACE group. This 
might also be related to the injection of the emulsion in the lobe artery (right and left 
hepatic artery) resulting in distributing the doxorubicin-containing emulsion in a larger 
liver volume and thereby affecting the liver function, while in DEB-TACE the injection 
of the suspension is done superselectively.  
The results of this study with its limited number of participants suggest that the overall 
response (%) after DEB-TACE treatment was higher but not statistically significant. A 
larger study population is needed to compare the response between these two 
treatments.   
There are other limitations with this study, including differences in the degree of 
embolization achieved, the sizes of the particles applied, the selectivity of the placement 
of the catheter for administration, the intrahepatic distribution of the drug-delivery 
system, the local drug concentrations (not normalized), the release rate of doxorubicin 
from the delivery device, and the size of the target lesion(s). All of these factors have an 
impact on tumor response after these two therapies, but their relative importance is 
unknown. However, these limitations are also valid for any assessment of clinical 
outcome for this treatment in other studies. 
However, these limitations are also valid for any assessment of clinical outcome for this 
treatment in other studies. 
5.3 PAPER	III	
The results from this study showed that in a real-life setting, patients with HCC 
tolerated DEB-TACE better than cTACE. The reason behind this is most probably the 
lower plasma doxorubicin level and the smaller AUC after DEB-TACE compared to 
after cTACE37, 84. 
The major strength of this study was the long follow-up (median 7.1 years), which 
enabled comparison of survival after the DEB-TACE and cTACE treatments. Another 
strength was the real-life setting, which enabled the evaluation of these two methods in 
clinical practice. There are two earlier studies with similar follow-up and cohort size as 
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ours, one from Germany 85 and one from Taiwan 86, both had smaller study populations 
and demonstrated similar effects for the two treatments on survival. However, median 
survival differed between these two studies (14–17 months versus 37 months, 
respectively) regardless of which treatment was given. This variation in survival 
between the studies reflects the variation in selection criteria in different regions in the 
world, the variation in underlying HCC etiologies in patients, and the heterogeneity of 
the patient groups 87. Very strict selection criteria have been shown to increase survival 
after TACE to up to 4 years 88. In our study we had a mixed cohort (BCLC B and C), 
which probably influenced the survival. 
The lack of randomization between the two treatment regimens and the fact that the two 
groups were not comparable in all aspects limited this study. Another limitation was 
due to changes in clinical factors such as CT protocols and improved diagnostic 
methodology over time because the two cohorts were treated over two different periods 
(2004–2008 vs. 2009–2012). However, having similar clinical routines, similar referral 
policies, and having the same staff at the angiography unit are factors that might have 
reduced the effect of time. We were not able to compare tumor response after the two 
treatments because arterial enhancement from residual viable tumor mass might be 
masked by the deposited radiopaque lipiodol at post-treatment CT.  
We cannot exclude bias due to improved skills and administrative routines owing to 
increased patient volumes and training. This would speak in favor of DEB-TACE, but 
despite that we could not demonstrate a significantly improved survival by DEB-TACE 
over cTACE in this real-life setting. Thus, the major observed improvement for our 
patients after the introduction of DEB-TACE was the decreased frequency of adverse 
events in conjunction with the treatment episode. 
5.4 PAPER	IV	
Doxorubicin is known to be ineffective as a systemic chemotherapy for RCC75. The 
significantly more extensive tumor necrosis observed in this study after DEB-TACE 
compared to after TAE was likely caused by combining the chemotherapeutic effect of 
doxorubicin with embolization. The randomized design and the similarity in tumor size, 
catheter positioning, embolic endpoint, and particle size in the two treatment groups, 
rendered other explanations unlikely. 
The significant correlation between the histopathological evaluation (on microscopy) 
and the radiological evaluation (on CT) shown by this study suggests that CT can be 
used to evaluate the grade of necrosis in RCC after DEB-TACE. However, studies with 
larger populations, a greater range in tumor size, and with longer follow-up are needed 
to validate this aspect more thoroughly and to assess the effect of palliative use of DEB-
TACE on survival in patients with RCC. 
Researchers have used transarterial alcohol injection to treat RCC, but that treatment 
has been shown to be painful, to require general anesthesia, and to require a mean 
length of hospital stay of approximately 4 days 72. The highest VAS scored in this study 
after DEB-TACE was 6 and no patient was hospitalized longer than one day. The 
tumors treated by DEB-TACE in this study had similar vascularization. All patients 
except for patient 11 were treated using particles in the size of 100–300 µm. Patient 11 
was treated by particles sized 75–150 µm that were injected into a separate vessel 
supplying a small portion of the tumor, whereas the rest of the tumor was treated also 
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by particles sized 100–300 µm. This made it impossible to evaluate the effect of the 
particle size on the outcome. 
No intratumoral arteriovenous shunts were identified in the treated tumors in this study, 
such shunts must be considered as an absolute contraindication to DEB-TACE because 
the particles would pass the shunt to reach the venous side and make their way to 
vessels in other organs e.g. the heart and the lungs. 
One patient had concomitant Parkinson disease that worsened during the study. The 
patient´s participation in this study delayed the operation and the patient became no 
longer eligible for surgery. Unfortunately, it was not possible to predict this drawback at 
the time of inclusion. The deterioration in Parkinson disease was not considered a 
reason to terminate the study, although the consequence was major for the patient. 
Sporadic viable tumor cells were identified on microscopy even in cases where 
complete response was observed on CT. This fact implies a very high risk of tumor 
recurrence after DEB-TACE and limits this procedure to palliation. This conclusion is 
supported by the fact that tumor recurrence was observed after 26 months in patient 7 
and after 14 months in patient 11 because the tumors in these two patients were 
observed instead of removed surgically. Therefore, it is imperative to clearly state that 
thermal ablation is a curative treatment in inoperable patients with RCC and should 
always be considered first.  
Although a statistically significant difference in outcome was observed between the two 
groups, the small population size limits this study and the results must be interpreted 
with caution. The size of the particles and the degree of stasis are two parameters that 
were determined by the interventionist, introducing a potential operator variation that 
was not controlled for. In patient 3, the CT evaluation showed no necrosis after TAI 
whereas microscopy revealed small necrotic areas that did not change the maximum 
diameter of the tumor after the treatment, hence the necrosis grade was scored 0%. The 
grade of tumor necrosis in patient 5 was also scored 0% when evaluated by CT whereas 
microscopy revealed 20% necrosis. Therefore, the cytoreductive effect of TAE might 
have been underestimated on CT. 
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6 CONCLUSIONS	
6.1 GENERAL	CONCLUSIONS	
DEB-TACE modifies the perfusion and vascularization of HCC. The drug-eluting 
embolic agent used in DEB-TACE has a more controlled and prolonged release of 
doxorubicin. DEB-TACE is a reliable treatment for unresectable HCC, and it might be 
superior to TAI and to cTACE by virtue of causing fewer and milder adverse effects. 
DEB-TACE seems to be more effective than TAE in treating RCC and can be used as a 
palliative treatment.  
6.2 SPECIFIC	CONCLUSIONS	
Paper I 
High arterial and low portal-venous perfusion of HCCs early after DEB-TACE 
indicates an incomplete response. Portal perfusion of HCCs was significantly higher in 
treated HCCs compared to non-treated (p = 0.01). 
Paper II 
Doxorubicin-in-lipiodol emulsion releases doxorubicin faster compared to drug-eluting 
beads in HCC patients and provides more extensive local and systemic exposure to both 
doxorubicin and doxorubicinol. Drug-eluting beads’ release is more controlled than a 
doxorubicin-in-lipiodol emulsion.  
Paper III 
In a real-life setting, the overall survival did not differ between cTACE and DEB-
TACE. Adverse effects were milder in the DEB-TACE group, and the post-treatment 
complication rate was similar.  
Paper IV 
Treatment with DEB-TACE and TAE was feasible and safe for treating localized RCC. 
DEB-TACE had a significantly more potent cytoreductive effect on treated RCCs 
compared to TAE as observed on CT examination and light microscopy. However, 
viable tumor cells were detected by microscopy even when CT showed total tumor 
necrosis, a fact that limits the use of DEB-TACE to palliation.  
 
 
 
48 
7 ACKNOWLEDGEMENTS	
My thanks, appreciation, and gratefulness to my supervisor Professor Rimma Axelsson who 
not only introduced me to the world of scientific research, but also believed in me and in my 
ideas.  
My gratitude to my co-supervisors Associate Professor Torkel Brismar and Associate 
Professor Per Stål, for their extensive effort and invaluable knowledge, experience and time.  
My sincere appreciation and gratefulness to:  
Professor Peter Aspelin, who will always be my idol, for his valuable effort, advice, and 
support. 
Laszlo Mihocsa and Helena Ivanics, who introduced me to the field of interventional 
radiology, taught and supported me. 
Carl Fredrik Engström, Mikael Åström, Klaus Lange, Martin Delle, Maria Vinell, Jan 
Engström, Bo Kalin, all interventional radiologists whom I have learned incredibly a lot from. 
Johana Hakumäki, Director of Imaging and Physiology at Karolinska University Hospital; 
Katarina Fredriksson, Head of abdominal radiology; and Maria Kristoffersen Wiberg, 
Former head of the Radiology Department at Karolinksa University Hospital in Huddinge for 
their support and help to make this project possible. 
The intervention team at Karolinska University Hospital, site Huddinge: Agneta Åström, 
Bariq Al-amiry, Anita Hällgren, Anneth Mihocsa, Eva Jonsson, Alexanda Lotak. Galina 
Netkacheva, Beata Samok, Tove Törner, Subeda Osman, Susanne Haglund, Rinne´ 
Hallberg, Erika Lagtun, Helena Johansson, Emma Eriksson (Vivi-Ann), Sonja Munoz and 
Marie Mäkelä for their valuable help, support, competence, and professionalism. 
My mentor Logman Hanare, for his support. 
Elsa Lilienberg, Ilse Dubbeldore, Rickard Nyman, Lars Lundell, Ove Gustafsson, Ramin 
Ghaffarpour, and Mikael Fischer for great collaboration and lots of hard work. 
Johan Teiler not only as a co-author, but also as a colleague and friend who carried out many 
of my duties during my absence from our clinic.   
Anders Svensson for his valuable explanations, discussions, and advice. 
All co-authors and especially Marquez, H. P., Haubenreisser, H., Mathew, R. P., Alkadhi, 
H., Henzler, T., Ebeling Barbier, C., Norén, A., Duraj, F., Hedeland, M., Bondesson, U., 
Sjögren, E., Lennernäs, H., Haji M., Seth E., Wahlin S., and Bozoki, B. for productive 
collaborations and discussions. 
Stefan Gabrielson, Nikos Kartalis, Aristeidis Grigoriadis, Louiza Loizou, and Katharina 
Brehmer for their advice and support. 
All my friends and colleagues at the Department of Radiology. 
And to my family. 
 
   49 
 
8 REFERENCES	
 1. Jemal,	A.,	Bray,	F.,	Center,	M.	M.,	Ferlay,	J.,	Ward,	E.,	&	Forman,	D.	(2011).	Global	cancer	statistics.	CA:	a	cancer	journal	for	clinicians,	61(2),	69-90.	
2. Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, et al. (2018). EASL 
clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 
3. Saar, B., & Kellner-Weldon, F. (2008). Radiological diagnosis of hepatocellular carcinoma. Liver 
International, 28(2), 189-199. 
4. Llovet, J. M., Brú, C., & Bruix, J. (1999). Prognosis of hepatocellular carcinoma: the BCLC staging 
classification. In Seminars in liver disease (Vol. 19, No. 03, pp. 329-338). © 1999 by Thieme Medical 
Publishers, Inc. 
5. Trevisani, F., D'Intino, P. E., Grazi, G. L., Caraceni, P., Gasbarrini, A., Colantoni, A., et al. (1996). 
Clinical and pathologic features of hepatocellular carcinoma in young and older Italian 
patients. Cancer: Interdisciplinary International Journal of the American Cancer Society, 77(11), 
2223-2232. 
6. Bialecki, E. S., & Di Bisceglie, A. M. (2005). Diagnosis of hepatocellular carcinoma. Hpb, 7(1), 26-
34). 
7. Bargellini, I., Battaglia, V., Bozzi, E., Lauretti, D. L., Lorenzoni, G., & Bartolozzi, C. (2014). 
Radiological diagnosis of hepatocellular carcinoma. Journal of hepatocellular carcinoma, 1, 137). 
8. Vilana, R., Forner, A., Bianchi, L., García-Criado, Á., Rimola, J., de Lope, C. R., et al. (2010). 
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar 
to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology, 51(6), 2020-2029. 
9. Cuenod, C. A., Leconte, I., Siauve, N., Resten, A., Dromain, C., Poulet, B., et al. (2001). Early 
changes in liver perfusion caused by occult metastases in rats: detection with quantitative 
CT. Radiology, 218(2), 556-561. 
10. Sahani, D. V., Holalkere, N. S., Mueller, P. R., & Zhu, A. X. (2007). Advanced hepatocellular 
carcinoma: CT perfusion of liver and tumor tissue—initial experience. Radiology, 243(3), 736-743. 
11. Fischer, M. A., Leidner, B., Kartalis, N., Svensson, A., Aspelin, P., Albiin, N., et al. (2014). Time-
resolved computed tomography of the liver: retrospective, multi-phase image reconstruction derived 
from volumetric perfusion imaging. European radiology, 24(1), 151-161. 
12. Fischer, M. A., Brehmer, K., Svensson, A., Aspelin, P., & Brismar, T. B. (2016). Renal versus splenic 
maximum slope based perfusion CT modelling in patients with portal-hypertension. European 
radiology, 26(11), 4030-4036. 
13. Yang, Z. F., & Poon, R. T. (2008). Vascular changes in hepatocellular carcinoma. The Anatomical 
Record, 291(6), 721-734.  
14. Fischer, M. A., Kartalis, N., Grigoriadis, A., Loizou, L., Stål, P., Leidner, B., et al. (2015). Perfusion 
computed tomography for detection of hepatocellular carcinoma in patients with liver 
cirrhosis. European radiology, 25(11), 3123-3132).  
15. Kim, S. H., Kamaya, A., & Willmann, J. K. (2014). CT perfusion of the liver: principles and 
applications in oncology. Radiology, 272(2), 322-344. 
16.  Wang, J. H., Wang, C. C., Hung, C. H., Chen, C. L., & Lu, S. N. (2012). Survival comparison 
between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage 
hepatocellular carcinoma. Journal of hepatology, 56(2), 412-418. 
17. Clark, T., Maximin, S., Meier, J., Pokharel, S., & Bhargava, P. (2015). Hepatocellular carcinoma: 
review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Current 
problems in diagnostic radiology, 44(6), 479-486 
18. Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005, May). Resection and liver transplantation for 
hepatocellular carcinoma. In Seminars in liver disease (Vol. 25, No. 02, pp. 181-200). Copyright© 
2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. 
19. Mazzaferro, V., Bhoori, S., Sposito, C., Bongini, M., Langer, M., Miceli, R., & Mariani, L. (2011). 
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 
years of experience. Liver transplantation, 17(S2), S44-S57. 
20. Jansen, M. C., Van Hillegersberg, R., Chamuleau, R. A. F. M., Van Delden, O. M., Gouma, D. J., & 
Van Gulik, T. M. (2005). Outcome of regional and local ablative therapies for hepatocellular 
carcinoma: a collective review. European journal of surgical oncology, 31(4), 331-347. 
50 
21. Zimmerman,	A.,	Grand,	D.,	&	Charpentier,	K.	P.	(2017).	Irreversible	electroporation	of	hepatocellular	carcinoma:	patient	selection	and	perspectives.	Journal	of	hepatocellular	carcinoma,	4,	49.	22. Dhanasekaran,	R.,	Kooby,	D.	A.,	Staley,	C.	A.,	Kauh,	J.	S.,	Khanna,	V.,	&	Kim,	H.	S.	(2010).	Comparison	of	conventional	transarterial	chemoembolization	(TACE)	and	chemoembolization	with	doxorubicin	drug	eluting	beads	(DEB)	for	unresectable	hepatocelluar	carcinoma	(HCC).	Journal	of	surgical	oncology,	101(6),	476-480.		23. Yao,	F.	Y.,	Kerlan,	R.	K.,	Hirose,	R.,	Davern,	T.	J.,	Bass,	N.	M.,	Feng,	S.,	et	al.	(2008).	Excellent	outcome	following	down-staging	of	hepatocellular	carcinoma	prior	to	liver	transplantation:	an	intention-to-treat	analysis.	Hepatology,	48(3),	819-827.	
24. Graziadei,	I.	W.,	Sandmueller,	H.,	Waldenberger,	P.,	Koenigsrainer,	A.,	Nachbaur,	K.,	Jaschke,	W.,	et	al.	(2003).	Chemoembolization	followed	by	liver	transplantation for hepatocellular carcinoma 
impedes tumor progression while on the waiting list and leads to excellent outcome. Liver 
Transplantation, 9(6), 557-563. 
25. Malagari, K., Chatzimichael, K., Alexopoulou, E., Kelekis, A., Hall, B., Dourakis, S., et al. (2008). 
Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: 
results of an open-label study of 62 patients. Cardiovascular and interventional radiology, 31(2), 269-
280. 
26. Terzi, E., Golfieri, R., Piscaglia, F., Galassi, M., Dazzi, A., Leoni, S., et al. (2012). Response rate and 
clinical outcome of HCC after first and repeated cTACE performed “on demand”. Journal of 
hepatology, 57(6), 1258-1267. 
27. Idée, J. M., & Guiu, B. (2013). Use of Lipiodol as a drug-delivery system for transcatheter arterial 
chemoembolization of hepatocellular carcinoma: a review. Critical reviews in 
oncology/hematology, 88(3), 530-549. 
28. Özcan, M. M., & Atalay, Ç. (2006). Determination of seed and oil properties of some poppy (Papaver 
somniferum L.) varieties. Grasas y aceites, 57(2), 169-174. 
29. Kan, Z.; Wright, K.; Wallace, S. Ethiodized oil emulsions in hepatic microcirculation: in vivo 
microscopy in animal models. Academic radiology 1997, 4, (4), 275-82. 
30. Tancredi, T.; McCuskey, P. A.; Kan, Z.; Wallace, S. Changes in rat liver microcirculation after 
experimental hepatic arterial embolization: comparison of different embolic agents. Radiology 1999, 
211, (1), 177-81. 
31. Dubbelboer, I. R., Lilienberg, E., Ahnfelt, E., Sjögren, E., Axén, N., & Lennernäs, H. (2014). 
Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-
delivery systems. Therapeutic delivery, 5(4), 447-466. 
32. Zeng, Q., Li, Y., Chen, Y., Ouyang, Y., He, X., & Zhang, H. (2004). Gigantic cavernous hemangioma 
of the liver treated by intra-arterial embolization with pingyangmycin-lipiodol emulsion: a multi-
center study. Cardiovascular and interventional radiology, 27(5), 481-485. 
33. Lilienberg, E., Ebeling Barbier, C., Nyman, R., Hedeland, M., Bondesson, U., Axén, N., & 
Lennernäs, H. (2013). Investigation of hepatobiliary disposition of doxorubicin following intrahepatic 
delivery of different dosage forms. Molecular pharmaceutics, 11(1), 131-144. 
34. Lencioni, R., De Baere, T., Burrel, M., Caridi, J. G., Lammer, J., Malagari, K., et al. (2012). 
Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): 
technical recommendations. Cardiovascular and interventional radiology, 35(5), 980-985.  
35. Lewis, A. L., & Holden, R. R. (2011). DC Bead embolic drug-eluting bead: clinical application in the 
locoregional treatment of tumours. Expert opinion on drug delivery, 8(2), 153-169. 
36. Biondi, M., Fusco, S., Lewis, A. L., & Netti, P. A. (2013). Investigation of the mechanisms governing 
doxorubicin and irinotecan release from drug-eluting beads: mathematical modeling and experimental 
verification. Journal of Materials Science: Materials in Medicine, 24(10), 2359-2370. 
37. Varela, M., Real, M. I., Burrel, M., Forner, A., Sala, M., Brunet, M., et al. (2007). 
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin 
pharmacokinetics. Journal of hepatology, 46(3), 474-481. 
38. Poon, R. T., Tso, W. K., Pang, R. W., Ng, K. K., Woo, R., Tai, K. S., & Fan, S. T. (2007). A phase 
I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting 
bead. Clinical Gastroenterology and Hepatology, 5(9), 1100-1108. 
39. Johnson, P. J., Kalayci, C., Dobbs, N., Raby, N., Metivier, E. M., Summers, L., et al. (1991). 
Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of 
coadministration of lipiodol. Journal of hepatology, 13(1), 120-127. 
40. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). Sorafenib in 
advanced hepatocellular carcinoma. New England journal of medicine, 359(4), 378-390. 
   51 
 
41. Brown, D. B., Gould, J. E., Gervais, D. A., Goldberg, S. N., Murthy, R., Millward, S. F., et al. (2009). 
Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting 
criteria. Journal of Vascular and Interventional Radiology, 20(7), S425-S434. 
42. Pleguezuelo, M., Marelli, L., Misseri, M., Germani, G., Calvaruso, V., Xiruochakis, E., et al. (2008). 
TACE versus TAE as therapy for hepatocellular carcinoma. Expert review of anticancer 
therapy, 8(10), 1623-1641. 
43. Malagari, K., Pomoni, M., Kelekis, A., Pomoni, A., Dourakis, S., Spyridopoulos, T., et al. (2010). 
Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland 
embolization with BeadBlock for hepatocellular carcinoma. Cardiovascular and interventional 
radiology, 33(3), 541-551. 
44. Raoul, J., Guyader, D., Bretagne, J., Heautot, J., Duvauferrier, R., Bourguet, P., et al. (1997). 
Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled–
iodized oil in the treatment of hepatocellular carcinoma. Hepatology, 26(5), 1156-1161. 
45.  Sangro, B., & Salem, R. (2014, November). Transarterial chemoembolization and radioembolization. 
In Seminars in liver disease (Vol. 34, No. 04, pp. 435-443). Thieme Medical Publishers. 
46. Riaz, A., Gates, V. L., Atassi, B., Lewandowski, R. J., Mulcahy, M. F., Ryu, R. K., et al. (2011). 
Radiation segmentectomy: a novel approach to increase safety and efficacy of 
radioembolization. International Journal of Radiation Oncology• Biology• Physics, 79(1), 163-171. 
47. Ljungberg, B., Campbell, S. C., Cho, H. Y., Jacqmin, D., Lee, J. E., Weikert, S., & Kiemeney, L. A. 
(2011). The epidemiology of renal cell carcinoma. European urology, 60(4), 615-621. 
48. Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W., & Charbonneau, C. (2008). Epidemiologic and 
socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer 
treatment reviews, 34(3), 193-205. 
49. Chow, W. H., Devesa, S. S., Warren, J. L., & Fraumeni Jr, J. F. (1999). Rising incidence of renal cell 
cancer in the United States. Jama, 281(17), 1628-1631. 
50. Patard, J. J., Leray, E., Rodriguez, A., Rioux-Leclercq, N., Guillé, F., & Lobel, B. (2003). Correlation 
between symptom graduation, tumor characteristics and survival in renal cell carcinoma. European 
urology, 44(2), 226-232.  
51. Kim, H. L., Belldegrun, A. S., Freitas, D. G., Bui, M. H., Han, K. R., Dorey, F. J., & Figlin, R. A. 
(2003). Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. The 
Journal of urology, 170(5), 1742-1746. 
52. Park, J. W., Jo, M. K., & Lee, H. M. (2009). Significance of 18F-fluorodeoxyglucose positron-
emission tomography/computed tomography for the postoperative surveillance of advanced renal cell 
carcinoma. BJU international, 103(5), 615-619. 
53. Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., et al. (2015). EAU 
guidelines on renal cell carcinoma: 2014 update. European urology, 67(5), 913-924. 
54. Volpe, A., Finelli, A., Gill, I. S., Jewett, M. A., Martignoni, G., Polascik, T. J., et al. (2012). Rationale 
for percutaneous biopsy and histologic characterisation of renal tumours. European urology, 62(3), 
491-504. 
55. Bielsa, O., Lloreta, J., & Gelabert-Mas, A. (1998). Cystic renal cell carcinoma: pathological features, 
survival and implications for treatment. British journal of urology, 82(1), 16-20. 
56. Kim, S. P., Alt, A. L., Weight, C. J., Costello, B. A., Cheville, J. C., Lohse, C., et al. (2011). 
Independent validation of the 2010 American Joint Committee on Cancer TNM classification for 
renal cell carcinoma: results from a large, single institution cohort. The Journal of urology, 185(6), 
2035-2039. 
57. Okhunov, Z., Shapiro, E. Y., Moreira, D. M., Lipsky, M. J., Hillelsohn, J., Badani, K., et al. (2012). 
RENAL nephrometry score accurately predicts complications following laparoscopic renal 
cryoablation. The Journal of urology, 188(5), 1796-1800. 
58. Joniau, S., Eeckt, K. V., Srirangam, S. J., & Van Poppel, H. (2009). Outcome of nephron-sparing 
surgery for T1b renal cell carcinoma. BJU international, 103(10), 1344-1348. 
59. Lane, B. R., & Novick, A. C. (2007). Nephron-sparing surgery. BJU international, 99(5b), 1245-
1250. 
60. Gratzke, C., Seitz, M., Bayrle, F., Schlenker, B., Bastian, P. J., Haseke, N., et al. (2009). Quality of 
life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and 
nephron-sparing surgery in patients with renal cell carcinoma. BJU international, 104(4), 470-475. 
61. Stern, J. M., Svatek, R., Park, S., Hermann, M., Lotan, Y., Sagalowsky, A. I., & Cadeddu, J. A. 
(2007). Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a 
renal tumours. BJU international, 100(2), 287-290. 
52 
62. Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., et al. (2011). A 
prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of 
elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell 
carcinoma. European urology, 59(4), 543-552. 
63. Sun, M., Becker, A., Tian, Z., Roghmann, F., Abdollah, F., Larouche, A., et al. (2014). Management 
of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for 
surgery and nonsurgical management. European urology, 65(1), 235-241. 
64. Van Poppel, H., & Joniau, S. (2007). Is surveillance an option for the treatment of small renal 
masses?. European urology, 52(5), 1323-1330. 
65. Aron, M., & Gill, I. S. (2007). Minimally invasive nephron-sparing surgery (MINSS) for renal 
tumours: Part II: probe ablative therapy. European urology, 51(2), 348-357. 
66. Ljungberg, B., Cowan, N. C., Hanbury, D. C., Hora, M., Kuczyk, M. A., Merseburger, A. S., et al. 
(2010). EAU guidelines on renal cell carcinoma: the 2010 update. European urology, 58(3), 398-406. 
67. Clark, T. W., Millward, S. F., Gervais, D. A., Goldberg, S. N., Grassi, C. J., Kinney, T. B., et al. 
(2009). Reporting standards for percutaneous thermal ablation of renal cell carcinoma. Journal of 
vascular and interventional radiology: JVIR, 20(7 Suppl), S409. 
68.  Ogan, K., Jacomides, L., Dolmatch, B. L., Rivera, F. J., Dellaria, M. F., Josephs, S. C., & Cadeddu, J. 
A. (2002). Percutaneous radiofrequency ablation of renal tumors: technique, limitations, and 
morbidity. Urology, 60(6), 954-958. 
69. Schwartz, M. J., Smith, E. B., Trost, D. W., & Vaughan Jr, E. D. (2007). Renal artery embolization: 
clinical indications and experience from over 100 cases. BJU international, 99(4), 881-886. 
70. Li, D., Pua, B. B., & Madoff, D. C. (2014, March). Role of embolization in the treatment of renal 
masses. In Seminars in interventional radiology (Vol. 31, No. 1, p. 70). Thieme Medical Publishers. 
71.  Sauk, S., & Zuckerman, D. A. (2011, December). Renal artery embolization. In Seminars in 
interventional radiology (Vol. 28, No. 4, p. 396). Thieme Medical Publishers. 
72. Munro, N. P., Woodhams, S., Nawrocki, J. D., Fletcher, M. S., & Thomas, P. J. (2003). The role of 
transarterial embolization in the treatment of renal cell carcinoma. BJU international, 92(3), 240-244. 
73. Albiges, L., Choueiri, T., Escudier, B., Galsky, M., George, D., Hofmann, F., et al. (2015). A 
systematic review of sequencing and combinations of systemic therapy in metastatic renal 
cancer. European urology, 67(1), 100-110. 
74. Anselmo Da Costa, I., Rausch, S., Kruck, S., Todenhöfer, T., Stenzl, A., & Bedke, J. (2017). 
Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. Expert 
review of anticancer therapy, 17(4), 357-368. 
75. Haas, N. B., Lin, X., Manola, J., Pins, M., Liu, G., McDermott, D., et al. (2012). A phase II trial of 
doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 
8802. Medical Oncology, 29(2), 761-767. 
76. Choi, J. W., Cho, H. J., Park, J. H., Baek, S. Y., Chung, J. W., Kim, D. D., & Kim, H. C. (2014). 
Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse 
lipiodol emulsions and drug-eluting beads. PloS one, 9(12), e115898. 
77. Sacks, D. (2003). Society of Interventional Radiology clinical practice guidelines. In Journal of 
Vascular and Interventional Radiology. 
78. Meyer, T., Kirkwood, A., Roughton, M., Beare, S., Tsochatzis, E., Yu, D., et al. (2013). A 
randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation 
vs embolisation alone for hepatocellular carcinoma. British journal of cancer, 108(6), 1252. 
79. Choi, J. Y., Lee, J. M., & Sirlin, C. B. (2014). CT and MR imaging diagnosis and staging of 
hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging 
aspects. Radiology, 272(3), 635-654. 
80. Kitao, A., Zen, Y., Matsui, O., Gabata, T., & Nakanuma, Y. (2009). Hepatocarcinogenesis: multistep 
changes of drainage vessels at CT during arterial portography and hepatic arteriography—radiologic-
pathologic correlation. Radiology, 252(2), 605-614. 
81. Miyayama, S., Matsui, O., Zen, Y., Yamashiro, M., Hattori, Y., Orito, N., et al. (2011). Portal blood 
supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: 
observation on CT during arterial portography. Hepatology Research, 41(9), 853-866. 
82. Shin, S. W. (2009). The current practice of transarterial chemoembolization for the treatment of 
hepatocellular carcinoma. Korean journal of radiology, 10(5), 425-434. 
83. Lewis, A. L., Gonzalez, M. V., Lloyd, A. W., Hall, B., Tang, Y., Willis, S. L., et al. (2006). DC bead: 
in vitro characterization of a drug-delivery device for transarterial chemoembolization. Journal of 
vascular and interventional radiology, 17(2), 335-342. 
   53 
 
84. van Malenstein, H., Maleux, G., Vandecaveye, V., Heye, S., Laleman, W., van Pelt, J., et al. (2011). 
A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for 
unresectable hepatocellular carcinoma. Oncology Research and Treatment, 34(7), 368-376. 
85. Kloeckner, R., Weinmann, A., Prinz, F., dos Santos, D. P., Ruckes, C., Dueber, C., & Pitton, M. B. 
(2015). Conventional transarterial chemoembolization versus drug-eluting bead transarterial 
chemoembolization for the treatment of hepatocellular carcinoma. BMC cancer, 15(1), 465. 
86. Liu, Y. S., Lin, C. Y., Chuang, M. T., Tsai, Y. S., Wang, C. K., & Ou, M. C. (2018). Five-year 
outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with 
hepatocellular carcinoma. BMC gastroenterology, 18(1), 124. 
87. Fako, V., & Wang, X. W. (2017). The status of transarterial chemoembolization treatment in the era 
of precision oncology. Hepatic oncology, 4(2), 55-63. 
88. Burrel, M., Reig, M., Forner, A., Barrufet, M., de Lope, C. R., Tremosini, S., et al. (2012). Survival of 
patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using 
Drug Eluting Beads. Implications for clinical practice and trial design. Journal of hepatology, 56(6), 
1330-1335. 
 
 
